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1 Introduction 
Surgeries and other invasive medical procedures are performed daily around the world. In the 
United States alone, an average of 48.3 million surgical and non-surgical procedures are performed 
every year. There is a broad range of procedures performed, such as those for the digestive system, 
musculoskeletal system, and nervous system (CDC, 2017). Prior to any procedure that is bound to 
breach the skin barrier, proper preparation of the surgical site is critical as the skin microbiome 
harbors a wide array of microorganisms. Though the majority of the microorganisms do not cause 
harm when on the skin, disruption of the skin barrier will allow the microorganisms to enter the 
body through the surgical site, or the incision. Consequently, antiseptic skin preparation 
applicators are routinely used to prepare the patient’s skin because they aid in the elimination of 
bacteria that can cause surgical site infection (SSI). One of the most commonly utilized and trusted 
skin preparation products contains chlorhexidine gluconate in an alcohol-based solution, which 
has been shown to be effective against bacteria, viruses, and fungi (Skyes and Weese, 2014). 
Chlorhexidine gluconate (CHG) is a broad-spectrum biocide that disrupts the bacterial cellular 
membranes of both gram-negative and gram-positive bacteria. Additionally, CHG has broad 
activity against anaerobes, yeasts, and some lipid-enveloped viruses. Its fungal coverage, however, 
is reduced compared to other skin preparation solutions, such as iodophors and alcohols (Reichman 
& Greenberg, 2009). In an alcohol-based solution, specifically isopropyl alcohol, CHG remains 
active on the skin for up to 48 hours following the evaporation of the alcohol, which in turn 
improves its efficacy as an antiseptic.   
While pre-surgical skin preparation is both important and a requirement, patients claim that 
the antiseptic solution is cold and uncomfortable when it comes in contact with their skin. The 
cause of this discomfort is the evaporative cooling properties of the isopropyl alcohol, which draws 
heat from the skin surface. This phenomenon is more commonly and comfortably experienced 
during perspiration. In an operating room, where ambient conditions are maintained at 
approximately 65 – 69 ℉ (18-20 ℃) with a humidity of 70%, the body naturally responds through 
the vasoconstriction of blood vessels to maintain core body temperature of 97.7 - 99.5 ℉ (36.5-
37.5℃) (Ballayante, 2009). When combined, the low ambient room temperature and the 
evaporative cooling on bare skin can be an unpleasant experience for the vulnerable patient. 
Furthermore, it is common to scrub the antiseptic solution in a layering method that requires 
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several applications to assure thorough surgical site preparation, which can easily amplify the 
extent of discomfort and poor experience for the patient.  
In an effort to better understand the extent of the design need, the team created a survey 
(Appendix A) that clinical staff from the UMMS Interventional Radiology department would use 
to ask patients about their skin preparation experience. The team’s goal was to receive quantitative 
and qualitative data that would validate the need for redesigning the current antiseptic applicator. 
After receiving IRB approval from WPI (Appendix B) and UMMS, the survey was given to Dr. 
Hussain and Dr. Ruppell, who then educated the staff on the context and manner in which the 
survey would be introduced to the patients. The team received 22 completed patient surveys from 
the UMMS staff and the results are provided in Appendix C. 91% of survey patients believed that 
a warm antiseptic solution would enhance their experience and 95% of patients found the antiseptic 
to be cold. 
Although overall patient safety is always the top priority, it is important to prioritize efforts 
dedicated to enhancing patient experience as much as possible, especially during a vulnerable time 
such as surgery. Studies in various healthcare settings have shown that patient experience can 
affect recovery. Those who reported a poor experience and improper treatment during a medical 
visit were more likely to have a slower recovery and not follow post-treatment protocol (Chatterjee 
et. al, 2012). Unfortunately, such lack of adherence can lead to an increased healthcare cost burden 
as utilization of healthcare services will increase, which may result in greater patient 
dissatisfaction (Chatterjee et. al, 2012).   
The overarching goal of this project is to reduce patient discomfort induced by the cold 
sensation felt after applying the antiseptic skin preparation solution during surgical preparation. 
Our project sponsor, Dr. Sarwat Hussain, and his team at University of Massachusetts Medical 
School (UMMS) perform a range of interventional radiology procedures that require the use of 
antiseptic skin preparation applicators as part of surgical preparation. A biomedical engineering 
design solution catered toward resolving some of the patient concerns can be integrated into the 
pre-surgical preparation phase of various procedures. Specifically, procedures that demand local 
or regional anesthesia, where the patient is still conscious or minimally sedated, could benefit from 
the design solution. Though the project’s need is sourced from the staff’s experience, the output 
of the research can benefit the large healthcare population due to the scope of surgical procedures 
worldwide.  
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2 Literature Review 
This literature review provides an overview of pre-procedural and pre-surgical skin 
preparation. It highlights a variety of different topics, including: 1) skin preparation procedure and 
regulations, 2) preparation applicators currently on the market and their thermal properties, 3) the 
importance of patient experience. Patients have stated that skin preparation is an uncomfortable 
part of procedures and surgeries that negatively affects their overall patient experience. By 
researching the properties and mechanism of action of the current solutions, the reason for their 
dissatisfaction became clear. From this, the goal of this project is to lessen or eliminate the 
discomfort experienced by patients in the most effective manner possible.  
 
2.1 Skin Preparation Procedures and Regulations 
Every year, approximately 232.4 million major surgeries occur around the globe (Weiser, 
2018). In the United States alone, over 48 million surgical and non-surgical procedures take place 
per year.  In order to prevent a potentially life-threatening infection, the skin must first be properly 
prepared before a procedure. Post-procedural infections increase a patient’s recovery time, 
decrease their overall experience, and can even be life-threatening. Due to the gravity of the 
potential consequences, special emphasis is placed on ensuring that skin preparation procedures 
follow certain regulations, such as those from the Association of Surgical Technologies (AST) and 
the U.S. Food and Drug Administration (FDA).  
 
2.1.1 Skin Preparation Procedures 
As previously stated, skin preparation is performed in order to prevent infection during any 
procedure or surgery that breaks the skin barrier. The skin microbiome is home to various types of 
microorganisms, such as Staphylococcus epidermidis and Staphylococcus hominis (World Health 
Organization, 2009). Although these microorganisms have no negative effect on the skin itself, the 
majority of surgical site infections occur when microbial flora enter the surgical wound. By 
properly preparing the skin, debris and microbes are removed, which prevents the growth of 
microbes during the procedure (AST Education and Professional Standards Committee, 2008). 
Thus, proper skin preparation is an integral part of any procedure that penetrates the skin barrier.   
As to be discussed in section 2.2, there are multiple types of antiseptic skin preparation 
products currently on the market. Regardless of the product used, specific protocol is followed to 
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ensure that the patient’s skin is properly prepared. Prior to performing skin preparation, the skin 
must first be cleansed of any soil, grease, blood, etc. with a fat solvent or degreaser (AST Education 
and Professional Standards Committee, 2008). Although this fat solvent or degreaser does not have 
to be aseptic, it must be non-irritating, non-flammable, and non-toxic. For the skin preparation 
itself, it is essential that sterile technique is utilized. Medical-grade gloves must be worn, and it 
must be ensured that they, along with the skin preparation applicator or sponge, do not come in 
contact with non-sterile items. There is currently not a standard skin preparation duration - it varies 
depending on the hospital and type of procedure being performed. However, enough preparation 
solution must be used, beginning at the incision site, to cover a circular four-inch radius (AST 
Education and Professional Standards Committee, 2008). Once a sufficient boundary of skin has 
been prepared, it is essential that the applicator or sponge does not again touch the clean areas. 
According to the AST, the most crucial aspect of skin preparation is that it progresses from a clean 
to dirty portion of the skin in order to prevent contamination (AST Education and Professional 
Standards Committee, 2008).   
 
2.1.2 Skin Preparation Regulations 
On account of the importance of skin preparation to the overall procedural or surgical 
experience, there are regulations in place from different organizations to ensure that protocol is 
followed. The first governing organization is the Association of Surgical Technologists - an 
organization of over 40,000 members that strives to ensure high quality patient care (“Association 
of Surgical Technologists”, n.d.). The AST currently has ten standards of practice in place 
regarding various aspects of skin preparation of a surgical patient, however three are of particular 
interest and importance to this project. The organization recommends in Standard of Practice III 
that alcohol is not used alone as an antiseptic agent. Alcohol’s antimicrobial action is the 
denaturing of proteins, with 60% to 95% alcohol being the most effective. It also possesses a broad 
spectrum of antimicrobial properties, such as the ability to destroy gram-positive and gram-
negative bacteria and multidrug-resistant (MDR) pathogens like MRSA, VRE, Mycobacterium 
tuberculosis, and fungi (AST Education and Professional Standards Committee, 2008). However, 
it does not have a long-lasting, cumulative activity and therefore should not be the sole 
antimicrobial agent used for a procedure of long duration (AST Education and Professional 
Standards Committee, 2008).  An additional AST Standard of Practice is Standard VIII, which 
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discusses manufacturer’s instructions for warming antiseptic agents. This standard states that if a 
skin preparation solution is warmed, one must ensure that it is not so hot as to cause a burn on the 
patient’s skin. Lastly, Standard of Practice II states that FDA-approved agents must be used that 
have immediate, cumulative, and persistent action (AST Education and Professional Standards 
Committee, 2008).  
As mentioned by AST Standard II, FDA regulations must be followed in the design and 
usage of a skin preparation product. In the United States, antiseptic agents are currently regulated 
by the FDA’s division of Over-the-Counter (OTC) Drug Products (“Safety and Effectiveness”, 
2017). The following standards should be accounted for, according to the FDA: 1) the ability to 
reduce transient microorganisms, 2) the possession of a broad range of antimicrobial properties, 
3) fast-acting and long-lasting activity, and 4) avoiding irritation to the skin (AST Education and 
Professional Standards Committee, 2008). Additionally, the FDA stated in 2017 that as of 
December 20, 2018, chlorhexidine gluconate (CHG) and iodophors will not be Generally 
Recognized as Safe (GRAS) for use in a healthcare antiseptic. Due to this, any OTC antiseptic 
products containing these as active ingredients will need to be approved, prior to beginning a 
marketing campaign, under a New Drug Application (NDA) or Abbreviated New Drug 
Application (ANDA) (“Safety and Effectiveness”, 2017). In the design of any new skin preparation 
solution, especially one that contains active ingredients not generally deemed safe, it is essential 
to take extra steps to gain FDA approval.   
 
2.2 Antiseptic Skin Preparation Products on the Market 
Depending on the medical procedure, there are various antiseptic skin preparation on the 
market for use. In 2013, the Association of Perioperative Registered Nurses (AORN), a leading 
advocate for “excellence in perioperative practice and healthcare”, published the Perioperative 
Standards and Recommended Practices document (AORN, n.d.). Recommendation III in the 
document states that “the antiseptic agent should be selected based on the patient assessment”, 
which includes assessing for allergies, sensitivities, contraindications, lesions and other tissue 
conditions (AORN, 2013). As published by the AORN, Table I and II below briefly summarize 
the activity and considerations for the most commonly used antiseptic solutions. More details 
regarding the common antiseptics are referenced in subsections below.   
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Table I. Activity and Considerations for Perioperative Skin Preparation Antisepsis  
Antiseptic Mechanism of Action 
Gram-
Positive 
Bacteria 
Gram-
Negative 
Bacteria 
Viruses 
Rapidity 
of Action 
Persistent/ 
Residual 
Activity 
Isopropyl Alcohol 
Denaturation of 
proteins 
Excellent Excellent Good Excellent None 
Chlorhexidine 
Gluconate 
Disruption of cell 
membrane 
Excellent Good Good Moderate Excellent 
Povidone-iodine 
(Betadine®️ 
Surgical Scrub) 
Oxidation/ 
substitution with free 
iodine 
Excellent Good Good Moderate Minimal 
Chlorhexidine 
gluconate with 
alcohol 
(ChloraPrepTM) 
Disruption cell 
membrane and 
denaturation of proteins 
Excellent Excellent Good Excellent Excellent 
Iodine-based with 
Alcohol 
(DuraPrepTM) 
Oxidation/ substitution 
by free iodine and 
denaturation of proteins 
Excellent Excellent Good Excellent Moderate 
Note. Reprinted from AORN: Perioperative Standards and Recommended Practices, Retrieved from 
https://www.hqinstitute.org/sites/main/files/file-attachments/skin_antisepsis_0.pdf, 2013 
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Table II. Activity and Considerations for Perioperative Skin Preparation Antisepsis Contd. 
Antiseptic Use on Eyes and Ears 
Use on Mucous 
Membranes 
Contraindications Cautions 
Isopropyl Alcohol 
Not allowed. Can cause 
corneal damage or 
nerve damage 
Not allowed N/A 
Flammable. Does not 
penetrate organic material. 
Optimum concentration is 
60% to 90%. 
Chlorhexidine 
Gluconate 
Not allowed. Can cause 
corneal damage and 
deafness if in contact 
with inner ear. 
Not encouraged. 
Use with caution. 
Known 
hypersensitivity to 
drug. 
Prolonged skin contact 
may cause irritation in 
sensitive individuals. 
Povidone-iodine 
(Betadine®️ 
Surgical Scrub) 
Allowed. Moderate 
ocular irritant. 
Allowed. 
Known sensitivity 
(shellfish allergies 
are not a 
contraindication). 
Prolonged skin contact 
may cause irritation. May 
cause iodism in susceptible 
individuals; avoid use in 
neonates. Inactivated by 
blood. 
Chlorhexidine 
gluconate with 
alcohol 
(ChloraPrepTM) 
Not allowed. Can cause 
corneal damage and 
deafness if in contact 
with inner ear. 
Not allowed. 
Known 
hypersensitivity. 
Flammable. 
Iodine-based with 
Alcohol 
(DuraPrepTM) 
Not allowed. Can cause 
corneal damage or 
nerve damage. 
Not allowed. 
Sensitivity to 
povidone-iodine. 
(shellfish allergies 
are not a 
contraindication.) 
Flammable. 
Note. Reprinted from AORN: Perioperative Standards and Recommended Practices, Retrieved from 
https://www.hqinstitute.org/sites/main/files/file-attachments/skin_antisepsis_0.pdf, 2013 
 
2.2.1 Alcohols 
As reported by the Centers for Disease Control and Prevention (CDC) in 2008, the term 
“alcohol” in a hospital setting can refer to either ethyl alcohol or isopropyl alcohol, which are 
available as the OTC household rubbing alcohol (CDC, 2008).   
 
Mechanism of Action  
Alcohol penetrates the bacterial cell wall and denatures intracellular proteins by disrupting 
the side chain intramolecular hydrogen bonding (Elmhurst College, n.d.). Because protein function 
and activity are heavily dependent on protein structure, disruption of the tertiary structure (Figure 
I) of a protein will cease its activity.   
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Figure I. Illustration of protein denaturation. Protein structure strongly dictates proper functionality. 
Therefore, if the tertiary structure is lost due to denaturation, protein will no longer perform its function. 
Alcohol-based antiseptics rely on the denaturation of protein as the primary mechanism of action to kill 
bacteria, viruses and fungi. Adapted from Phys Org, P. Rüegg, 2017, Retrieved from 
https://phys.org/news/2017-02-rare-proteins-collapse-earlier.html 
 
Advantages  
Alcohols, like ethyl alcohol and isopropyl alcohol, are widely accepted as they target 
broad-spectrum bacteria. Because alcohol molecules participate in two hydrogen bonds while 
water molecules participate in four, alcohols (180.7 °F) have a lower boiling point than water         
(212 °F) (UCSB ScienceLine, n.d.). A lower boiling point is advantageous because it allows 
alcohol-based antiseptic solutions to evaporate quicker than aqueous-based solutions. Ultimately, 
the reduced drying time on the skin makes alcohols a preferred base for preoperative skin antiseptic 
solutions.  
 
Disadvantages  
Although alcohol is recognized for its antimicrobial properties and is an accepted antiseptic 
agent, “it should not be used as the single agent but as part of the skin prep regimen” (AST 
Education and Professional Standards Committee, 2008). In simpler terms, alcohol is not a 
sufficient preoperative antiseptic solution when used alone. As previously mentioned, the AST 
states that although alcohol is suitable for skin preparation due to its rapid and antimicrobial 
activity, it alone does not have a persistent, cumulative activity. Persistent, cumulative activity is 
a desired and crucial property for antiseptics because it helps decrease rebound microbial growth 
after initial skin preparation.  
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2.2.2 Aqueous-Based and Alcohol-Based Chlorhexidine Gluconate  
Chlorhexidine has been a trusted antimicrobial across various healthcare categories as it is 
incorporated in oral rinses, skin antiseptics, medical supplies and equipment, and antimicrobial 
dressings (Toomey, 2013). A stable salt form of free base chlorhexidine, chlorhexidine gluconate 
(CHG) is a widely used biguanide and biocidal agent in healthcare, mainly in dental hygiene 
and preoperative skin preparation (ChloraPrepTM), because of its effectiveness against gram-
positive bacteria, gram-negative bacteria, fungi, and viruses (McDonnell and Russell, 1999). 
Furthermore, CHG is a form of chlorhexidine salts that has the ability to dissolve in water and 
deliver the molecule in an effective way.  
 
Mechanism of Action 
Because CHG has a positive charge, it reacts with the negatively-charged microbial cell 
surface and absorbs into bacterial cells. CHG molecules disrupt the integrity of the cell wall and 
penetrate the cell well via passive diffusion, which subsequently damages the bacterial cytoplasm 
(McDonnell and Russell, 1999). Cell wall and cytoplasmic damage is then followed by the leakage 
of intracellular constituents and consequent cell death. CHG follows a similar mechanism of action 
against yeast. However, CHG’s effectiveness against viruses is variable in that its activity is 
restricted to lipid-enveloped viruses, which suggests that CHG is not effective against 
nonenveloped viruses such as rotavirus, Hepatitis A virus, and poliovirus. Table III below 
summarizes the CHG’s mechanism of action against various microorganisms.  
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Table III. Mechanisms of Antimicrobial Action of Chlorhexidine 
Type of 
Microrganism 
Action 
Bacterial spores 
Not sporicidal but prevents development of spores; inhibits spore outgrowth but not 
germination 
Mycobacteria Mycobacteristatic (mechanism unknown) but not mycobactericidal 
Other non-
sporulating bacteria 
Membrane-active agent, causing protoplast and spheroplast lysis; high concentrations 
cause precipitation of proteins and nucleic acids 
Yeasts 
Membrane-active agent, causing protoplast lysis and intracellular leakage; high 
concentrations cause intracellular coagulation 
Viruses 
Low activity against many viruses; lipid-enveloped viruses more sensitive than non-
enveloped viruses; effect possibly on viral envelope, perhaps the lipid moieties 
Protozoa Membrane activity (leakage) toward trophozoites, less toward cysts 
Note. Reprinted from Clinical Microbiology Review: Antiseptics and Disinfectants: Activity, Action, and 
Resistance, Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC88911/, 1999 
 
Advantages 
Introduced in to the United States in the 1970s, CHG has been recognized as a gold-
standard as there are several advantages of using it as an antimicrobial agent in skin preparation 
solutions. According to the World Health Organization, the antimicrobial activity of chlorhexidine 
is “not seriously affected by the presence of organic material, including blood” (2009). 
Furthermore, CHG is an even more effective antimicrobial agent when it is used in alcohol-based 
solutions, like 70% isopropyl alcohol. Attributed to its substantiativity, CHG can bind to proteins 
present on skin tissue and mucous membranes with limited systemic or bodily absorption. As a 
result, the protein-bound CHG adheres to the stratum corneum (uppermost top layer of skin) and 
provides an inhibitory effect on microbial growth by remaining on the skin after rinsing or drying. 
Nonetheless, alcohol-based CHG (ChloraPrepTM) has a residual activity of up to 48 hours - about 
8 times greater than that of aqueous-based CHG (World Health Organization, 2009).   
 
Disadvantages  
Because chlorhexidine is a cationic molecule, its activity can be reduced by natural soaps, 
various inorganic anions, non-ionic surfactants, and hand creams containing anionic emulsifying 
agents (World Health Organization, 2009). Although rare, prolonged contact can cause irritation 
and potentially dermatitis, making it less suitable for patients with sensitive skin. Specifically, 
chlorhexidine molecules can induce IgE-mediated anaphylaxis (Toomey, 2013). When individuals 
are exposed to a trigger antigen, like CHG, their immune system responds by activating production 
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IgE antibodies, which then attach to the surface membrane of mast cells and cause a “priming” 
effect (Toomey, 2013). Re-exposure or continued exposure to the antigen leads to rapid binding 
of antigen to the IgE antibodies of primed mast cells, which activates the mast cells that release 
allergenic mediators (histamine, cytokines, and leukotrienes) that account for the signs and 
symptoms of anaphylaxis.  
 
2.2.3 Aqueous-Based and Alcohol-Based Iodine Solutions  
In the early 1900s, iodine became recognized as an effective antimicrobial agent. However, 
following incidences of skin irritation and toxicity caused by iodine, povidone-iodine (PVP-I) was 
developed. PVP-I, or PI, is a stable chemical complex of polyvinylpyrrolidone (povidone/PVP) 
and elemental iodine (I) (Burks, 1998). PVP-I is safer than iodine alone as it has a lower 
concentration of free iodine at about 9-12%. Popular antiseptic skin preparation products that 
incorporate aqueous- based and alcohol-based iodine include Betadine®️ Surgical Scrub (PVP-I) 
and DuraPrepTM (iodine povacrylex in isopropyl alcohol), respectively. 
 
Mechanism of Action 
Apart from being effective against broad-spectrum bacteria, PVP-I can also kill viruses and 
fungi. PVP-I causes protein denaturation and precipitation of bacteria, which results in the death 
of the pathogenic microorganisms on the skin surface (“PubChem”, n.d.). Specifically, iodine 
molecules “rapidly penetrate the cell wall of microorganisms” and “inactivate cells by forming 
complexes with amino acids and unsaturated fatty acids”, which impairs protein synthesis and 
alters cell membranes (World Health Organization, 2009).  
 
Advantages 
One of the main advantages of aqueous-based PVP-I is that is can be used on the eye and 
ear unlike alcohols or CHG antiseptics. Apart from its versatility, PVP-I is effective against broad-
spectrum bacteria, viruses, and fungi. In alcohol-based solutions, antimicrobial activity is 
improved, and the duration of persistent/residual activity increased from 2 hours (aqueous-based) 
to 48 hours (Hemani and Lepor, 2009).  
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Disadvantages 
Despite its advantages, there are several disadvantages of PVP-I antiseptics. Unlike 
ChloraPrepTM, Betadine®️ Surgical Scrub and DuraPrepTM are inactivated by presence blood and 
organic matter, which reduces the solution’s antimicrobial properties (Hemani and Lepor, 2009). 
An in-vitro research study completed in the mid-1980s aims to explain this phenomenon as the 
team states that when iodine binds to organic substances like blood, pus, fat, and glove powder, 
there is decreased iodine availability to kill the bacteria present on the skin (Zamora et. al, 1985). 
Another study, which focused on comparing antiseptics to prevent catheter-related infections, 
suggested that povidone iodine is inactivated by protein-rich biomaterials, like blood, present on 
the skin (Goudet et. al, 2013). Additionally, prolonged skin contact can cause irritation and 
sensitivity. 
 
2.3 Prevalence of Medical Equipment Warming in Care Delivery 
In humans, normal core body temperature (normothermia) is 37°C (John et. al, 2014). When 
core body temperature drops below 36°C, a patient is considered to be hypothermic. Meanwhile, 
operating rooms are typically kept below 23°C. Although medical personnel wearing layers of 
clothing and personal protective equipment consider 23°C to be warm, patients that are undressed 
and simply covered by a surgical gown feel otherwise. Apart from a cold ambient room 
temperature, it has been shown that surgical patients lose 0.25°C of body temperature for every 
liter of intravenous (IV) fluid administered (Rose et. al, 2013).  Although IV fluids are not 
administered for every procedure, a 0.25°C body temperature change is a significant temperature 
drop that should be considered.  
Studies have shown that there is a relationship between hypothermia in surgical patients and 
their risk of surgical site infection. Clinically, hypothermia can induce perioperative wound 
infections by eliciting vasoconstriction and impaired immunity. Lack of tissue oxygen and 
collagen deposition, due to vasoconstriction, can then defer proper wound healing (Rose et. Al, 
2013). Unfortunately, perioperative hypothermia has been shown to increase the length of hospital 
stays, cause cardiovascular stress, and decrease patient satisfaction (Rose et. al, 2013).   
In an effort to mitigate the various causes of hypothermia, hospitals invest in warming 
equipment such as blanket and fluid warmers, which are discussed in more detail in section 4.3. 
Such equipment allows cotton blankets, intravenous fluid, and irrigation fluid to be kept at 
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temperatures above room temperature so that they can serve as a source of warmth to the patient 
when in use.  
 
2.4 Thermal Properties 
There are many thermal properties that contribute to the uncomfortable, cold sensation that 
patients experience when being prepared for a procedure or surgery. These properties and 
principles include evaporative cooling, as well as other physical and chemical properties of 
the ChloraPrepTM solution. 
 
2.4.1 Evaporative Cooling 
Evaporation is the process by which a liquid transforms to a gaseous state (Lohner, 2017). 
With a sufficient amount of energy any liquid can evaporate. The amount of energy needed for 
this phase change to occur is defined as the heat of vaporization. More specifically, the heat of 
vaporization is the amount of heat required to transform one gram of a liquid into a gas, without 
increasing the temperature of the liquid (Kirkham, 2014). It is important to note that the heat of 
vaporization is a latent heat. This means that the heat of vaporization is marked by a change in 
phase, not in temperature. The heat of vaporization varies depending on the liquid being observed 
as well as the surrounding temperature. For example, less energy is needed to vaporize liquid in 
warm temperatures than in cold temperatures (Lohner, 2017).   
When a liquid changes to a gaseous state, hydrogen bonds must be broken. The more 
hydrogen bonds a molecule can form, the greater its heat of vaporization will be because more 
energy is required to break these bonds. Molecules with more hydrogen bonds will also have higher 
boiling points. Typically, liquids with lower boiling points will evaporate at a faster rate than 
liquids with higher boiling points (Lohner, 2017).   
When gas flows over a liquid, it is called evaporative cooling (Bergman et al., 2011). 
Evaporation occurs when molecules at the surface of a liquid begin colliding with one another. For 
the process of evaporation to be sustained, internal energy must be provided from the liquid. This 
causes a reduction in temperature of the liquid, otherwise known as the cooling effect. However, 
to maintain steady-state conditions, the latent energy that the liquid loses needs to be restored 
through the transfer of energy to the liquid from its surroundings. This energy transfer can come 
from convection of energy from the gas or the addition of heat by other means.  
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An example of evaporative cooling that is present in daily life is the process of perspiration. 
Perspiration allows the human body to maintain homeostasis through the regulation of 
temperature. Typically, perspiration occurs due to an increase in environmental temperatures or 
the commencement of physical activity/exercise. The body is able to transform perspiration from 
its liquid form to a gaseous form. This process requires energy which is taken in the form of heat. 
The resulting heat transfer causes a cooling effect (Lohner, 2017).    
 
2.4.2 Physical and Chemical Properties of ChloraPrepTM solution 
As discussed in the previous section, there are certain properties of a liquid that will cause 
it to evaporate at a faster rate and have a greater heat of vaporization. As a baseline, water has a 
boiling temperature of 100℃ (212℉).  Alcohol, on the other hand, has a boiling temperature of 
82℃, which is significantly lower than that of water (Lohner, 2017). For this reason, alcohol will 
evaporate at a much faster rate than water. This means that the cooling effect of alcohol is greater.   
Some other relevant properties of isopropyl alcohol and the ChloraPrepTM solution are 
compared in Tables IV and V below. Unfortunately, there are a lot of properties of 
the ChloraPrepTM solution that the manufacturer does not disclose. Because the solution contains 
isopropyl alcohol, those values will be utilized as estimates. 
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Table IV. Properties of Isopropyl Alcohol 
(Stockmen's Supply, 2018) 
Property Associated Value/Information 
Color Clear 
pH 6-8 
Melting Point Not available 
Freezing Point -89.5℃ 
Boiling Point 190℉ 
Flash Point 77℉ 
Flammable Limits 2%-12% 
Vapor Pressure 25 mm Hg at 66℉ 
Explosive 
Properties/Limits 
Containers exposed to intense 
heat should be cooled with 
water to prevent vapor pressure 
build-up, which could result in 
container rupture. 
 
Table V. Properties of ChloraPrepTM Solution 
(Medline, 2017) 
Property Associated Value/Information 
Color Clear, orange, or teal 
pH 7 - 7.5 
Melting Point Not available 
Freezing Point Not available 
Boiling Point Not available 
Flash Point 67℉ 
Flammable 
Limits 
2%-12% 
Vapor Pressure Not available 
Explosive 
Properties/Limits 
Not available 
 
 
2.5 Importance of Patient Experience 
Patient experience is a subjective factor in every hospital that should not be overlooked. It 
reflects the healthcare system and therefore should optimally serve society by satisfying its 
customers (Jackson, 2001). One way of quantifying this service is given by The Centers for 
Medicare and Medicaid Services who has a Value-Based Purchasing Program that includes 
Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores. The 
HCAHPS scores measures the patient's’ impression of care during their stay at a hospital or 
healthcare facility and is mandatory for hospitals to receive any payments from Medicare. Those 
facilities that do not meet a defined performance standard are penalized through reductions in 
Medicare payments (Ehwerhemuepha, 2018). Hospitals enrolled in Medicare care plans have 
better performance in dealing with customer service and obtaining information on health plans in 
the US (Jha, 2008).   
The HCAHPS survey asks 27 questions about the patients’ experience in the hospital and 
demographics. A few questions relate to communications with physicians, nurses, about 
medication, quality of nursing services, planning for discharge, pain management, room 
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cleanliness and quietness. The survey also asks a global rating of the hospital on a 0 to 10 scale 
and whether the patient would recommend the hospital to family and friends, Hospitals with a high 
level of patient satisfaction such as those in the top quartile of HCAHPS ratings are of better quality 
than those in the bottom quartile (Jha, 2008).  
One study examined the effects of three variables on patient experience. These three 
variables pertaining to the nurse staffing included staffing levels, skill mix, and staffing flexibility. 
They found that staffing flexibility has the most positive impact on patient experience. Many 
nurses work part-time because their job can be stressful with increased understaffing and irritable 
patients. Part-time employment can reduce burnout for employees of this profession and improve 
performance. A less taxing working environment can elicit better patient care compared to full-
time nurses (Oppel, 2018).  Although nurses do not prepare the skin, this provides useful insight 
into what factors affect patient experience.  A friendly staff member who mentions that a cold 
sensation will be felt gains the patients trust. A patient who trusts their caregivers will feel more 
comfortable and satisfied with their experience. Warm sensations can elicit feelings of comfort 
that a cold sensation cannot. A warm antiseptic solution could make a small impact on the patients’ 
experience before a procedure. Nurse staffing could help with this type of impact on patient 
experience based on how they are trained to treat the patient.  
Patients of all ages must be considered. In pediatrics, a study analyzed clinical variables and 
psychosocial factors as well as the child HCAHPS survey responses (Ehwerhemuepha, 2018). A 
few of the clinical variables mentioned were length of stay, pain intensity scores, number of 
chronic conditions, number of hospitalizations, and inpatient surgeries. Some psychosocial 
variables included were legal custody issues, domestic concerns, alternate medical care and request 
for spiritual care. They found that parents who are dealing with custody issues, have a male child, 
or have a child with a chronic medical condition are less likely to recommend the hospital. This 
may relate to the stress of going through custody battles and familial hardships. If the parents feel 
like the caregiver did not explain what to look for after they were discharged or that the doctor did 
not listen to them or ask questions that a family member would know best about the child, they are 
less likely to recommend the hospital and perceive that the nurses did were not respectful and 
courteous. Meanwhile parents of low socioeconomic status and those with children who do not 
have chronic medical conditions are more likely to recommend the hospital. This may relate to 
different expectations of care and the need for more complex care. Although the child HCAHPS 
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scores give a general indicator of the importance of hospital to patient communication, the 
responses are from the children’s parents, not the patient themselves.  
The adult HCAHPS scores are taken from the adult patients themselves. About 2429 scores 
had low scores in pain control and discharge instructions. Patient experience can vary across 
regions and reflects the difference in quality management and organizational leadership (Jha, 
2008). Unmeasured variables such as cultural differences and expectations of care at for-profit and 
not-for-profit hospitals may have an impact in experience as well. While people who are older are 
more likely to give positive recommendations compared to younger people as reported by a study 
on the predictors of patient satisfaction, this only accounts for a small percentage of the total effect 
on satisfaction after adjustments are made according to their satisfaction models (Jackson, 2001). 
Communication barriers such as unfriendly doctors, lack of empathy and enthusiasm, failure to 
consider patient’s concerns, lack of explanation about the patient's condition, and excessive use of 
medical jargon are also only a small portion of the significant factors. Poor mental and physical 
health may influence satisfaction, but not as much as the health outcomes of the visit. While this 
study only used how patients would in theory judge satisfaction, 80% said that the health outcome 
was the most important variable along with unmet expectations, of which hospital staff are not 
aware. The team hopes to alleviate one source of unease for the patient in an attempt to increase 
satisfaction.   
 
2.6 Injection and Blow Molding of Disposable Medical Devices 
In the manufacturing of medical devices with plastic components, there are two types of 
molding processes that are regularly used – injection molding and blow molding. Both 
manufacturing processes have their benefits, however, choosing one is typically based on the type 
of product being produced.  
While utilized to produce medical devices, injection molding is also used to manufacture 
common, everyday items – from small plastic parts, to chairs, to automobile parts. Injection 
molding has become of interest to the team as the manufacturing method of a redesigned skin 
preparation applicator due to its economic viability and the volume of product it can quickly 
produce. Additionally, injection molding allows for complex parts to be produced in a single rapid 
and automatic operation, unlike other manufacturing processes (Ebnesajjad, 2015). It is this single 
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operation that allows injection molding to be economically feasible, despite the high cost of 
molding press machines and molds due to the high pressures they are required to withstand.  
Conventional injection molding is a simple, understandable principle. Simply put, during 
injection molding, a melted polymer is injected into a mold where it can cool and mold to the shape 
of the desired product (Seow and Lam, 1997). To go into more detail, the chosen plastic resin, a 
thermoplastic polymer, is heated until it converts from a solid polymer to a molten fluid with low 
viscosity. The melted resin is then injected into a closed mold of the chosen product shape within 
the molding press. The low viscosity of the molten resin allows for the mold to fill completely. 
High injection pressures are needed due to the viscosity of the melts, so a large amount of force is 
needed to hold the mold closed while it is filling. The material is then cooled until it solidifies, and 
then the mold is open, and the finished part is removed (Ebnesajjad, 2015). Although the principle 
is simple to understand, the practice of injection molding can be complex due to the complexity of 
some plastic melts and the design of molds needed to produce a product.  
While conventional molding is useful for solid parts, it does not allow for the manufacturing 
of hollow or thin-walled products. Gas-assist injection molding was created in order to overcome 
this shortcoming. The process to produce a gas-assist injection process differs from the 
conventional process: first, pressurized nitrogen gas is injected into the melt and permeates the 
part (Hansen, 2005). Next, compressed nitrogen gas is injected. During the injection of this gas 
through the plastic’s core, a portion of the molten plastic is displaced. Following the gassing phase, 
pressure is released by gas recycling or by releasing the gas back into the atmosphere. Once 
ambient pressure is obtained, the final part is then ejected from the mold (Hansen, 2005). Gas-
assist can be used for simple hollow, tube-shaped parts and thin-walled parts, and is more versatile 
than conventional injection molding.  
In addition to injection molding, blow molding is also a manufacturing method being 
considered by the team. Blow molding is typically used to manufacture high volume, one-piece 
hollow products. Products that are typically blow molded are items such as water or soda bottles, 
shampoo bottles, or any other hollow plastic product. Like injection molding, the shape of the end 
product is determined by the mold details (Lee, 2000).  
The blow-molding process utilizes a parison, or pre-form, that is a plastic resin hot tube (Lee, 
2000).  This pre-form is placed within a split mold that has a hollow cavity. The sides of the mold 
are then clamped shut together, which seals the pre-form. Air is blown into the tube, expanding 
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the wall of the melted resin into the desired shape of the cavity. Following this, the mold is cooled 
with water. This solidifies the resin into the shape of the part so that it can be ejected from the 
mold. Once the part is ejected, it typically requires trimming of excess product and finishing (Lee, 
2000). The blow molds used have a number of parts, but most commonly consist of two halves. 
These halves, when closed, form a cavity that enclose the pre-form, mentioned above, for blowing. 
These mold haves contain built-in channels for the cooling water used to solidify the molded 
product (Lee, 2000).  
Unlike injection molding, blow molding does not require high clamping or blow pressures 
(Lee, 2000). Therefore, the blowing mold does not need to be made with a high tensile strength 
material. However, a high tensile strength material is typically recommended for molds with a 
long production run – these molds are usually made of steel. Typically, though, blow molds are 
machined from aluminum billet, cast aluminum alloys, zinc alloys, or bronze (Lee, 2000).  
Both injection and blow-molding are practical manufacturing options for the redesigned skin 
preparation applicator. The selection of a final manufacturing method will be based on the final 
product design, and the volume of sticks to be produced.  
 
2.7 Prototyping of Medical Devices 
         While a medical device design is still being finalized, it is essential to create prototypes. 
These prototypes allow the design team to create improved iterations of the device, by putting each 
prototype through a set of different tests. Once the final prototype is perfected, the design can then 
go on to be mass manufactured.  If the final design includes plastic components, the manufacturing 
process often includes injection or blow molding, as discussed in section 2.6.  
          The MQP team will begin by creating prototypes of their final chosen design. When 
prototyping, typically designers have the option to 3D print components. For this project the team 
will send a SolidWorks model to a rapid prototyping lab in order to 3D print the stick component 
of our skin preparation stick. However, the team also must purchase additional materials such as 
sponges and rubber and self-assemble them with the 3D printed stick. This step is necessary in 
order to fully test our prototype and identify any changes that need to be made.  
          Prototyping often does not stop at just one prototype. Time depending, the team expects to 
have three different iterations of their design by the end of this project. Each design will include 
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minor changes and any improvements we deem necessary during testing. It is not until the final 
prototype functions optimally that the design is able to be manufactured. 
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3 Project Strategy 
A project strategy has been established in order to ensure that the project has a positive final 
outcome.  This section of the report outlines ideas about the solution to the team’s design, and 
what the team intends to do in the project. It first begins with the initial client statement. Then, 
technical design requirements are discussed along with design requirements based on standards. 
A revised client statement is discussed. Lastly, a management approach of the project is explained.  
 
3.1 Initial Client Statement 
As presented by the team’s advisor, Professor Jeannine M. Coburn, PhD and sponsor, Dr. 
Sarwat Hussain, MD, the initial client statement is:   
 
“Develop a method to integrate warming into skin preparation applicators for interventional 
or surgical applications.”   
 
This statement is sourced from Dr. Hussain’s personal experiences when attending patients in 
the Interventional Radiology department at UMass Medical School. As previously mentioned, Dr. 
Hussain states that the alcohol-based antiseptic solution causes discomfort in patients in the form 
of a chilling sensation upon application.  
Throughout the course of the team’s initial literature review, along with discussions with 
both Professor Coburn and Dr. Hussain, a revised client statement has been developed in Chapter 
3.4. 
 
3.2 Design Requirements – Technical 
This section discusses the various design requirements of the project. First, the project 
objectives will be identified. Then, the different constraints will be outlined. Lastly, design 
functions and specifications will be presented.   
 
3.2.1 Objectives 
Based on the initial client statement, the team gathered more information through meetings 
with their advisor as well as through research. Using this information, the team was able to develop 
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several objectives, which are listed below. These objectives are ranked based on importance in a 
pairwise comparison chart.   
 
1. Design or develop a device or method for pre-warming the skin preparation 
applicator: The problem that Dr. Hussain has observed with the current process of skin 
preparation is the shocking cold sensation experienced during skin preparation. The low 
boiling point of isopropyl alcohol causes it to evaporate at a faster rate than water. This 
property combined with the ambient temperature in the operating/procedure room 
(which is below typical room temperature) causes an extremely cold sensation when the 
antiseptic is applied.  
2. Improve overall patient experience: Surgical and other medical procedures put 
patients in an already vulnerable and anxious position. Any discomfort that can be 
avoided/eliminated during a surgery or procedure should be taken into consideration. 
Increased patient comfort and satisfaction has been shown to improve the healing 
process.   
3. Create a universal design that could be applied to comparable skin preparation 
applicators on the market:  For the purposes of research and design, the team is 
focusing on the ChloraPrepTM skin preparation applicator. Despite this, it is the team’s 
goal to develop a device or method that could be easily adapted to any other skin 
preparation applicators on the market. This would allow the team’s device to be 
accessible to a wider patient population. 
4. Ensure safety of the patient and medical staff: The antiseptic solution used in the skin 
preparation applicators can be flammable or even explosive when heated past certain 
temperatures. The team must ensure that the applicator is warmed to a temperature that 
will not put the patient or medical team in danger.   
5. Create a cost-effective device that is not a significant cost increase from the current 
devices on the market: While patient experience is important, it may not be prioritized 
over cost if the new device is significantly more expensive than current devices. For this 
reason, the added cost must be worth the added value. *The team will add current 
product cost from a reliable source. We plan to ask Dr. Hussain how much UMMS pays 
  
 
23 
 
for the product in bulk and how the insurance company reimburses the hospital. Once 
this information is obtained, this objective will be clarified and expanded on. *   
6. The device should maintain its original functionality: Skin preparation applicators 
are ultimately used to eliminate bacteria and other contaminants from the surgical site. 
The new design must maintain the antimicrobial properties of the current devices on the 
market.   
 
3.2.2 Constraints 
Something necessary to consider in the design requirements of the project are different 
constraints. The constraints that were identified must be considered to define the limitations of the 
project, along with its success. The identified constraints and their definitions can be seen in the 
Table VI below.  
Table VI. Applicable Project Constraints 
Constraint Definition 
Budget A total budget of $1000 
Time Project must be completed by April 19, 2019 
Sterility Device must be contained in a sterile package 
User Friendly Should not require additional training to medical personnel 
Inexpensive Fabrication Cost increase should be less than 25% (subject to change) 
FDA & AST Regulations Must satisfy current regulations regarding proper surgical preparation procedures 
  
The project team must work within these limitations to successfully complete the project. 
The first constraint identified is the budget. The team has an overall budget of $1000, or $250 per 
team member, for testing, prototyping, and purchasing materials. The second constraint is time. 
The project must be completed by project presentation day, which falls on April 19, 2019. School 
breaks (e.g. WPI vacation days, national holidays) must also be accounted for within this 
constraint. The third constraint is sterility. Currently, skin preparation applicators are contained in 
a sterilized package and any modification made must not interfere with the device’s ability to be 
contained in a sterile package. Additionally, modifications to the device designed must also be 
sterilized. Regarding device handling and use, the device must remain user-friendly and require 
no additional training to medical personnel. It should also be inexpensive to fabricate, and not 
require a price increase of more than 25%. Lastly, the device should continue to satisfy FDA and 
AST standards for surgical preparation procedures.   
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3.2.3 Functions 
The team identified the key functions for the redesigned skin preparation applicator, which 
are explained in Table VII.  The primary function of this project includes reducing the amount of 
patient discomfort by warming the antiseptic solution by approximately 10°C. Through various 
heat loss calculations performed, it was determined that raising the temperature by 10°C should 
essentially eliminate the initial chilling sensation when the antiseptic fluid is applied on the 
patient’s skin. Ideally, the temperature of the antiseptic be about that of skin. However, to prevent 
skin irritation or burns, the temperature of the antiseptic should not be increased to a value beyond 
body temperature. Possible means of achieving the function of warming the antiseptic solution 
include dry heat, hot water bath, or heat of mixing reaction. Dry heat such as steam or hot glass 
beads could warm the solution and sterilize at the same time, however this requires additional 
machinery which is expensive and takes up space. A hot water bath will not maintain sterility if 
the device is opened outside of its original packaging. If the device is still in the original sterile 
packaging, the whole package would have to be submerged into the bath. This would include the 
paper materials and safety sheet along with the device which is not ideal because the goal is to 
warm the antiseptic solution, not the whole device including material and safety sheet. The last 
means of achieving the function is the heat of mixing reactions. This mean was chosen because 
the reaction can take place directly outside of the antiseptic solution holding tube. The materials 
are inexpensive, accessible, and do not require additional machinery since they can be used inside 
of the device.  
The second design function is a method of releasing the antiseptic solution from its 
container. At first a shaking mechanism could be used in order to break a membrane that separated 
the solution from outside of the device. This was ruled out because depending on how sensitive or 
fragile the membrane was, it could be easily broken or fractured during transport thereby starting 
the reaction prematurely. Another means was to squeeze the inner tube to break and release the 
solution. This is how the solution is administered in the current applicator stick, but this method 
does not include a warming function. Squeezing to fracture was ruled out because there exists the 
possibility of the antiseptic solution mixing with the heat of mixing reaction. If mixing occurs, the 
solution may lose antiseptic properties and the reaction products could end up being administered 
onto the patient’s skin. The last mean was the use of pull tabs. Separate chambers each holding 
either the antiseptic solution or the heat of mixing products would be sealed using rubber pieces 
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cut to fit the opening of the chambers. When these rubber tabs are pulled, the contents of that 
chamber will be allowed to flow to the destination.   
 
Table VII. Design Functions 
Design Function Means of Achieving Function 
Warming antiseptic 
solution 
Dry heat Hot water bath Heat of mixing reaction 
Release of antiseptic 
from inner tube 
Shaking device 
Squeezing inner tube to 
fracture 
Pull tabs 
 
3.2.4 Specifications 
The design must fall under specifications determined by the team. These specifications 
include warming the antiseptic solution to 40°C that will reduce patient discomfort. Additionally, 
the device must hold no less than 10.5 mL of antiseptic solution because this is the smallest amount 
of fluid one applicator can hold. The device must also maintain its original antiseptic properties in 
order to reduce the risk of infection. This is quantified by a 4-log It is essential that the warmed 
antiseptic solution kill just as much bacteria as the currently used model. The device must also be 
able to undergo a sterilization process before use. Since skin preparation sticks are often used in 
surgical suites, they must be contained in sterile packaging in order to avoid bring contaminated 
items into the suite. Finally, the team determined that the new device should not have a 
significantly higher price than those currently on the market. The team’s prototype cost $57 to 
produce, however this was 3d printed as a single device. When manufactured on a large scale, this 
price should decrease significantly.  For the most patients to benefit from the warming skin 
preparation applicator, insurance companies must be willing to cover the cost of the new device.  
 
3.3 Design Requirements – Standards 
This section discusses different industry, engineering, and regulatory standards. Topics such 
as sterility and the warming of antiseptic agents will be discussed. Additionally, the team will also 
cover other standards such as those from the Association of Surgical Technologists (AST), US 
Food and Drug Administration (FDA), and the International Organization for Standardization 
(ISO). 
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3.3.1 Association of Surgical Technologists (AST) 
The first set of standards that the team will adhere to are the ones set in place by the 
Association of Surgical Technologists (AST). The AST has ten standards of practice for skin 
preparation on a surgical patient. The ChloraPrepTM applicator that is currently used, along with 
the team’s future modifications, are expected to follow these standards. Although skin preparation 
applicators fall within the overarching category of skin preparation, three AST standards are 
directly relevant to them: Standard of Practice II, Standard of Practice III, and Standard of Practice 
VIII. It is critical that the team’s final design satisfy these AST standards in order to ensure a safe 
device that is able to benefit patients during their pre-procedural skin preparation.    
Standard of Practice II specifies that for pre-procedural skin preparation, healthcare 
facilities should use FDA-approved agents that possess immediate and persistent antimicrobial 
properties (AST Education and Professional Standard Committee, 2008). FDA standards will be 
discussed in section 3.3.2. Standard of Practice III states that alcohol should not be used as a single 
agent for pre-procedural antiseptic purposes. For the team’s design to be considered effective by 
the AST, alcohol may be used, but an additional, longer-lasting antiseptic agent must be included 
(AST Education and Professional Standards Committee, 2008). Standard of Practice VIII states 
that if a skin preparation solution is flammable, it must not be warmed, per manufacturer's 
instructions. This standard is of particular interest and concern to the team, as warming skin 
preparation solution is one of the goals of the project. 
 
3.3.2 U.S. Food and Drug Administration (FDA) 
The project team also must abide by current FDA regulations. Antiseptic agents, such as 
those within a skin preparation applicator, are regulated under the FDA’s Over-the-Counter Drug 
Products division (“Safety and Effectiveness”, 2017). It is stated that when antiseptic agents are 
being chosen, the following factors must be considered: 
1. The ability to reduce transient microorganisms   
2. The possession of a broad range of antimicrobial properties  
3. Fast-acting and long-lasting activity  
4. Potential irritation to the skin  
Additionally, the team’s final design would require additional FDA approval. As of December 20, 
2018, chlorhexidine-gluconate and iodophors will not be generally recognized by the FDA as safe 
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for use in antiseptics (“Safety and Effectiveness”, 2018). The team’s current plan is to modify a 
pre-existing skin preparation applicator that contains chlorhexidine-gluconate. This means that in 
order for modification and updated product to be FDA approved, a New Drug Application will 
need to be submitted.   
 
3.3.3 International Organization of Standardization (ISO) 
The final set of standards to be considered by the team are ISO standards. The first ISO 
standard of importance to this project is ISO 11737-2:2009 – Sterilization of Medical Devices. 
This standard “specifies the general criteria for tests of sterility on medical devices that have been 
exposed to a treatment with the sterilizing agent reduced relative to that anticipated to be used in 
routine sterilization processing” (“ISO”, 2015). The standard states that the tests should be done 
while defining, validating, or maintaining a sterilization process. Additionally, ISO 13485:2016 
must be considered. This standard sets requirements for the quality management systems within 
the medical device industry (“ISO”, 2016). Furthermore, ISO 15378:2017 is an application 
standard regarding the packaging materials used for medical devices. If the team decides to alter 
the ChloraPrepTM packing material, or applicator material itself, then this standard must be 
considered ("ISO”, 2017). Additionally, with any modifications of materials comes further 
material testing. ISO 10933-1:2018 is a standard that applies to any medical devices that indirect 
or direct contact with the patient’s body during intended use (“ISO”, 2018). This document 
specifies how to assess the biological safety of a medical device through appropriate methods and 
tests. This standard will be adhered to by the team in order to ensure proper testing is performed 
regarding the safety of our device.  
 
3.3.4 European Standards and Criteria  
To confirm that the redesign of the device does not jeopardize the effectiveness of the 
antiseptic solution, the team considered the European standards and criteria that the ChloraPrepTM 
antiseptic solution is currently compliant with. European (EN) standards are voluntary standards 
ratified by one of three European Standards Organizations ("What is a European Standard”, 2019). 
According to the ChloraPrepTM Summary of Product Characteristics document, because it a 
product used worldwide, the antiseptic solution meets the following criteria from chemical 
disinfectants and antiseptic products established by European Standards: EN 1040, EN 1275, EN 
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13727, and EN 13624 (ChloraPrepTM, 2016). Although the team’s new product was designed in 
the United States, in order to effectively market it it in the future, all current standards should be 
upheld. The following text explains each standard the performance criteria to meet the standard, 
and the general protocol each standard follows (Accuratus Lab Services, n.d.). 
 EN 1040: Basic Bactericidal Activity of Chemical Disinfectants  
o EN 1040 is designed to evaluate the basic bactericidal activity of chemical 
disinfectants and antiseptics.  
o For an antiseptic agent to meet the criteria of EN 1040, there must be at least a 5-
log reduction in test organism viability after exposure to the antiseptic for a 
maximum of 5 minutes.  
 
 EN 1275: Basic Fungicidal or Basic Yeasticidal Activity of Chemical Disinfectants 
o EN 1275 is designed to evaluate the basic fungicidal or yeasticidal activity of 
chemical disinfectants and antiseptics.  
o For an antiseptic agent to meet the criteria of EN 1275, there must be at least a 4-
log reduction in test organism viability after exposure to the antiseptic for a 
maximum of 15 minutes.  
 
 EN 13727: Bactericidal Activity in the Medical Area 
o EN 13727 is designed to evaluate the bactericidal activity of products (i.e. 
handwashes and disinfectants) that are used in the medical area.  
o For an antiseptic agent to meet the criteria of EN 13727, there must be a 3- to 5-log 
reduction in test organism viability after exposure to the antiseptic for 1 to 5 
minutes, based on the specific protocol or claim.  
 
 EN 13624: Fungicidal or Yeasticidal Activity in the Medical Area 
o EN 13624 is designed to evaluate the fungicidal or yeasticidal activity of products 
that are used in the medical area. 
o For an antiseptic agent to meet the criteria of EN 136274, there must be a 4-log 
reduction in test organism viability after exposure to the antiseptic for a maximum 
of 60 minutes. 
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The European Standards mentioned above all call for of a suspension-based study to be 
completed, in which the test organism (i.e. microbial/bacterial agent) is exposed to a test sample 
(i.e. chlorhexidine gluconate in isopropyl alcohol). After reaching the target exposure time, the test 
suspension solution in neutralized to halt further antimicrobial activity of the antiseptic solution. 
To test for test organism survival, samples from the suspension solution are plated and incubated. 
After incubation, a reduction in viability is determined by comparing the plated sample to the 
initial bacterial count and the bacterial count on the control plate. 
 
3.4 Revised Client Statement 
Following further discussion of the project requirements, the revised client statement for the 
project is:   
 
“Develop a device improvement or a skin preparation method that can reduce patient 
discomfort during antiseptic application.” 
 
The team revised the client statement in an effort to broaden the scope of project design. 
Rather than limiting the scope to adding an element in the current device design that will warm 
the patient’s skin, the team understands that root source of the project need is the patient 
discomfort. Any design that will reduce discomfort with improve patient experience.  
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3.5 Management Approach 
In an effort to address the constraint of time, the team is following a Gantt chart (Figure 
II) that was created to display key hard and soft deadlines and project phases.  
 
 
Figure II. Gantt Chart  
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4 Design Process 
Following the development of a project strategy, the design process begins. The project 
strategy is how the team created a plan for the successful completion of this project. Within the 
project strategy, the design requirements for the project were stated and ranked based on 
importance. This chapter will begin with a need analysis, which will rank objectives by weight. It 
then moves into a discussion regarding conceptual design. The different means by which the 
project objectives could be accomplished are then identified and discussed. Finally, all alternative 
designs are evaluated in order to choose the most feasible and effective final design. 
 
4.1 Needs Analysis 
The project objectives were ranked by importance by the project team. Table VIII below 
lists the project objectives in order of importance.  
 
Table VIII. Pairwise Comparison of Project Objectives  
 Patient 
Experience 
Universal Safe 
Cost-
Effective 
Functional 
Patient 
Experience 
- 0.5 1 0.5 1 
Universal 1 - 1 1 1 
Safe 0.5 0.5 - 0.5 0.5 
Cost-
Effective 
1 0.5 1 - 1 
Functional 0.5 0.5 1 0.5 - 
Total 3 2 4 2.5 3.5 
  
In Table VIII above, the - symbol represents a null value and is used when comparing two 
identical needs. A score of 0.5 is given when the need in the column is deemed less important than 
the need it is being compared to in the row. Finally, a score of 1 means that the need in the row 
was identified as less important than the need in the column.  
Following the prioritization of the project objectives, the team identified the wants and needs. 
In this case, a need is something that is essential for the project to be successful. Based on the 
ranked objectives seen in Table 2, the needs for this project were identified to be: safety, 
functionality, and improved patient experience.   
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For this project, a “want” is something that, while it may beneficial to have, is not critical. 
Although the identified “wants” could improve the outcome of the project, they are not necessary 
in order to complete the project successfully. Based on the ranked objectives from the table above, 
the wants were identified to be cost effectiveness and a warming method. 
 
4.1.1 Objective Definitions  
Following the ranking of the project objectives, it is important to understand what is meant 
by each of them. The first objective considered was patient experience. When designing a new 
skin preparation applicator, one of the team’s goals is to enhance the overall patient experience. 
The team hopes that this can be achieved by providing them with an improved preparation process 
for their procedures. The next objective was universality. Although the team is primarily designing 
a skin preparation application that contains Chlorhexidine Gluconate, the team hopes to create a 
universal design that can also be used for other skin preparation solutions. Next is safety. It is 
imperative that the skin preparation procedure remains safe for both the patient and medical 
personnel, with no risk of injury. Another objective is for the device to be cost-effective. For the 
team’s new design to have the largest impact on patient experience, it is critical that the design is 
covered by insurance companies. To ensure this, the price of the new device should not increase 
substantially. Finally, the team considered functionality. While our goal is to enhance the patient 
experience, it remains vitally important that the applicator performs its original function – to 
reduce the presence of bacteria on the skin before a procedure.  
 
4.2 Conceptual Design and Concept Map 
In order to produce a preliminary conceptual design for a skin preparation applicator with 
warmed solution, it is easiest to divide the design into smaller sections. The first part to consider 
is the type of antiseptic being used in the updated skin preparation applicator. Dr. Hussain, the 
team’s sponsor, would like to continue using ChloraPrepTM applicators as skin preparation agents. 
Thus, this is the primary target for the design team. However, alternative antiseptic solutions, such 
as those that contain povidone iodine, should be considered to determine which can be heated most 
efficiently while retaining their antiseptic properties. Next, the general warming method must be 
selected. The sponsor’s preference is to warm the antiseptic solution by way of a modification to 
the physical skin preparation applicator. The team will also consider other options, such as 
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externally warming the applicator or a method of pre-treating the patient’s applicator, to ensure 
that an applicator modification is the best choice. The specific warming mechanism will then be 
chosen by the team. For example, if the team decides on designing a modification to the applicator, 
the specific warming method then needs to be determined. The team will consider different 
options, such as various exothermic reactions. Finally, any new device designs or modifications 
needed to house the warming method will be created. These steps to creating a final conceptual 
design can be seen in Figure III below.   
 
Figure III. Concept map for the warming of a skin preparation applicators 
 
4.3 Alternative Designs 
Based on the team’s initial research, it was clear that there were three general methods that 
could be executed to fulfill the needs of the client: external warming, internal warming, 
and desensitization of the skin.  These methods have been analyzed in depth in the following 
sections. Ultimately, one method will be selected as the final design solution.  
 
4.3.1 External Warming Methods 
Warming the skin preparation applicator using an external method would involve 
increasing the temperature of the antiseptic solution via a heating source that is not integrated with 
the existing device. In other words, an external heating method would not require any changes be 
made to the existing device. Instead, an external device would be designed/utilized as a source of 
heat for the skin preparation applicators. The following are potential solutions utilizing an external 
method of warming.   
  
4.3.1.1 Dry Heating Unit 
The team could design a device, much like an incubator, that utilizes a form of dry heat 
(such as steam or hot glass beads) to keep the antiseptic solution in the device warm. This device 
would be installed permanently in procedure rooms and/or operating rooms and the skin 
Select 
antiseptic 
solution
Select general 
warming 
method
Select specific 
warming 
mechanism
Create physical 
device designs 
or modfications
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preparation applicators would be stored inside until use. Currently, healthcare settings, including 
UMMS, rely on warming cabinets that warm medical blankets to comfort patients and increase a 
patient’s body temperature. Pedigo, a medical equipment company, manufactures warming 
cabinets that warm cotton blankets. Additionally, Pedigo manufactures fluid warming cabinets that 
are designed to warm medical irrigation and intravenous fluids. Warming fluids above room 
temperature can reduce the severity and potentially lower the incidence of perioperative 
hypothermia (Singh et. al, 2014). In addition to blanket and fluid warming cabinets, healthcare 
settings also utilize warmers, like the THERMASONIC® Gel Warmer, to warm ultrasound gels to 
body temperature prior to use. Although these solutions exist and are used in industry, a barrier or 
disadvantage of such equipment is the cost. Table IX below provides the manufacturer's suggested 
retail price (MSRP) of the equipment mentioned above (Universal Medical Inc., 2019). The retail 
cost of the equipment appears to be the main drawback. For example, if a hospital were to 
supply every unit that uses irrigation or intravenous fluid with a fluid warming cabinet like the 
Pedigo Solution Warming Cabinet, the total cost would easily reach hundreds of thousands of 
dollars. 
 
Table IX. Cost of External Medical Product Warming Equipment (Universal Medical Inc., 2019) 
Blanket Warmer Fluid Warmer Ultrasound Gel Warmer 
Pedigo Blanket  
Warming Cabinet 
Compartment Size: 2.3 cubic feet 
MSRP: $4,438.70 
 
Pedigo ivNow Fluid 
 Warming Pod 
Compartment Size: 3 fluid bags 
MSRP: $3,846.00 
 
THERMASONIC Gel Warmer 
Compartment Size: 3 gel bottles 
MSRP: $223.00 
Pedigo Blanket Warmer  
with Dual Glass 
Compartment Size: 20.6 cubic feet 
MSRP: $13,991.40 
Pedigo Solution  
Warming Cabinet 
Compartment Size: 7.7 cubic feet 
MSRP: $15,394.90 
 
 
4.3.1.2 Hot Water Bath 
The team could design a hot water bath with temperature controls to warm the skin 
preparation applicators prior to use. This hot water bath would ideally by stored in the 
procedure/operating room and the skin preparation applicators could be retrieved as needed before 
the procedure. The biggest challenge with this design idea is the ability to maintain the sterility of 
the skin preparation applicator. Skin preparation applicators are contained within sterilized 
packaging. Placing the packaged skin preparation applicator in a hot water bath would jeopardize 
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the sterility of the skin preparation applicator (as the water would likely soak through the 
packaging, which is partially composed of paper). 
 
4.3.2 Internal Warming Methods 
Warming the skin preparation applicators using an internal warming method would involve 
integrating a heating component directly into the design of the skin preparation applicator. This 
would require a redesign of the existing device to incorporate a heating element. The following 
are some potential solutions that utilize an internal method of warming. 
 
4.3.2.1 Exothermic Reactions 
By definition, exothermic reactions are chemical reactions that release energy in the form 
of heat into the surrounding as a product of the reaction (Bergman et. al, 2011). The following 
equation represents this phenomenon:  
 
𝐴 + 𝐵 → 𝐶 
 
The team researched three exothermic reactions that could potentially warm the antiseptic 
solution stored inside the glass ampoule of the ChloraPrepTM applicator. The three exothermic 
reactions are as follows:  
 
Sodium Acetate Crystallization 
 
𝐶𝐻3𝐶𝑂𝑂
− (𝑎𝑞) + 𝐻2𝑂 (𝑙) → 𝐶𝐻3𝑂𝑂𝐻 (𝑎𝑞) + 𝑂𝐻
− (𝑎𝑞) 
 
With a heat of fusion ranging from 264–289 kJ/kg, the crystallization of sodium acetate 
from a supersaturate solution is a phenomenon that is used in conventional hand warmers. A 
solution of concentrated aqueous salts is sealed in a flexible container with a metallic activator 
strip usually made of stainless steel. The metal strip is bent, and crystals begin to precipitate. When 
the first crystal forms, the whole pack fills with solid crystalline needles of sodium acetate. This 
crystal formation releases heat and the temperature rises to 130 °F for approximately 30 minutes 
(Supersaturated solution, 2013). In small quantities with controlled heat production, this reaction 
could be beneficial towards our objective of internally warming the antiseptic solution.   
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Quicklime and Water 
 
𝐶𝑎𝑂 (𝑠) + 𝐻2𝑂 (𝑙) → 𝐶𝑎(𝑂𝐻)2 (𝑎𝑞) 
 
Quicklime (calcium oxide) and water are known to produce an exothermic reaction (United 
States Patent, 1985). It is used as a device for heating food in a sealed container such as a tin, can 
or carton without the use of external heat. The benefits of this approach are that it does not generate 
hydrogen gas as a byproduct as other common exothermic reaction do such as magnesium and 
water (Researchers Submit Patent Application, 2013). The quicklime is separated from the water 
by a watertight seal or membrane that is easily broken using mechanical means. Water and 
quicklime produce heat, which is transferred by conduction to the food in the container. Some 
drawbacks of this method are the amount of water needed to produce this reaction, more than 
three-parts water by weight to one-part by weight of quicklime. This could pose a problem to the 
team’s design because the preparation applicator must be comfortable to hold. A large amount of 
water in the device would increase the size. Also, the presence of humidity of the air can damage 
the quicklime and reduce the heating capacity. The energy of the system is low, approximately 1.2 
kJ/g of calcium oxide (Researchers Submit Patent Application, 2013). The mixture is not 
homogeneous, so uneven heating may occur. Strong heating causes the production of water vapor 
which increases the pressure inside the vessel and can cause explosions.   
 
Porous Oxygen Activated Heater  
 
𝑀𝑔 (𝑠) + 2𝐻2𝑂 (𝑙) → 𝑀𝑔(𝑂𝐻)2 (𝑠) + 𝐻2 (𝑔) 
 
While current flameless heaters use water to produce heat, water can be a hassle to carry 
in the device and the hydrogen gas byproducts create safety, storage, and disposal concerns. 
Oxygen-based heaters do not require water to generate heat. They only generate heat in the 
presence of oxygen which allows the reaction to be stopped and started by preventing or allowing 
oxygen access. Since oxygen is abundant in the atmosphere, this reaction does not require 
additional components in order to be initiated, only oxygen from the atmosphere. The porosity of 
the composite is what determines the efficiency of the heater. Since the Rechargeable Battery 
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Corporation sought a patent for porous oxygen activated heaters, more information needs to be 
researched. An example of this can be seen in Flameless Ration Heater (FRH). An improved 
flameless ration heater is used in US Army Meals Ready to Eat (MRE) which does not require 
water to heat the meals. This lowers the cost, weight and transportation burden of the other heating 
method. There is no hydrogen gas produced and the air activated heater can heat the meal 100 
degrees Fahrenheit in less than 10 minutes (No water needed in new Army MRE heaters, 2015).  
The team will use this research regarding existing exothermic reactions to redesign 
the ChloraPrepTM applicators to incorporate an internal warming method.  
 
4.3.3 Desensitization of Patient Skin 
Desensitization of the patient’s skin is a method that does not involve changing the skin 
preparation applicators in any way. Instead, the patient’s skin would be treated to reduce sensation 
in the area that required preparation. Desensitization techniques to decrease nerve pain include a 
program where the patient can either put the wounded area in baths with contrasting temperatures. 
This eventually trains the skin to feel cooler in the cold bath and warmer in the warm bath. Another 
technique is touch stimulation. Starting with a cotton ball, the painful area is stroked in one 
direction followed by a soft fabric such as silk, then a rougher fabric such as a towel. Eventually 
pain tolerance is increased with the stimulations in the wounded area (Back in Motion Physical 
Therapy, 2018).   
 
4.3.4 Pre-warming of Patient Skin 
Pre-warming the patient’s skin could reduce the shockingly cold sensation felt during the 
application of the antiseptic solution. One way in which this pre-warming can be achieved is 
through capsaicin. Capsaicin is “a selective activator of the chemo- and heat-sensitive transient 
receptor potential (TRP) V1 cation channel”, that also gives chili peppers their intense heat (Janos, 
2015). In humans it has been found that at a concentration of 2 × 10−7 g/ml, capsaicin causes a 
warm sensation. In animal experiments, capsaicin has also shown to cause sensory desensitization 
(Janos, 2015). If applied to the patient’s skin before the antiseptic solution, capsaicin can 
potentially reduce the sensation of the evaporative cooling from the ChloraPrepTM.  
             Additionally, prior to the application of the antiseptic solution, the skin could be warmed 
using a forced-air blanket. Forced-air blankets are commonly used to warm a patient’s skin surface 
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prior to the induction of anesthesia, in order to avoid hypothermia during surgery (Shin, 2015). 
One study showed that these blankets can increase core body temperature before surgery by as 
much as 0.5°C. Although patients’ body temperatures still decreased throughout the procedure, by 
starting with a higher core temperature, they only dropped to 36°C as opposed to 35°C (Shin, 
2015).  Pre-warming the patient’s skin with forced-air blankets could increase their starting skin 
temperature, and potentially decrease the cold sensation of ChloraPrepTM.  
 
4.4 Final Design Selection 
At this stage in the completion of the project, the team has finalized their design. In order to 
come to reach this final design, the team conducted literature review and calculations to determine 
an effective chemical reaction to cause heating. Additionally, the team designed multiple physical 
applicator prototypes, constrained by the current size of the ChloraPrepTM stick and the preferences 
of our sponsor. Additionally, antimicrobial testing was completed in order to ensure the 
effectiveness of the ChloraPrepTM solution as a disinfectant after being warmed.  
 
4.4.1 Heat Loss Background Information  
Energy can take three main forms: kinetic energy, potential energy, and internal energy. 
Kinetic energy, Ek, is the energy possessed by a moving system due to its velocity. Potential 
energy, Ep, is a result of the position of a system in a gravitational or electromagnetic field or do 
to the conformation of the system relative to equilibrium. Internal energy, U, is the energy 
transferred as a result of any driving force, excluding a difference in temperature.  
Energy can be transferred as heat or work. Heat energy is a type of energy that causes flow 
across system boundaries due to a temperature difference between the system and its surroundings. 
Work is energy transferred as a result of any driving force, excluding a difference in temperature. 
Enthalpy, H, is the combination of two energy terms. It can be described by the following 
equation:  
 
𝐻 = 𝑈 + 𝑝𝑉 
 
The variables are defined as follows: 
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 𝑈 = 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑒𝑛𝑒𝑟𝑔𝑦 
 𝑝 = 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 
 𝑉 = 𝑣𝑜𝑙𝑢𝑚𝑒 
 
Specific enthalpy, h, is calculated using a similar, but slightly different equation: 
 
ℎ = 𝑢 + 𝑝𝑣 
 
The variables are defined as follows: 
 𝑢 = 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑒𝑛𝑒𝑟𝑔𝑦 
 𝑝 = 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 
 𝑣 = 𝑣𝑜𝑙𝑢𝑚𝑒 
 
 Enthalpy, H, is an extensive value meaning that it is dependent on the size of the 
system. Specific enthalpy, h, on the other hand, is a specific quantity.  
To understand the mechanism of heat transfer, it is crucial to understand the general 
principles of energy balances. In an energy balance, energy can be neither created nor destroyed. 
Instead, energy is transferred from one form to another. This can be expressed as a simple 
mathematical idea by saying the energy that leaves the system can be subtracted from the energy 
that enters the system to determine the amount of energy that has accumulate in the system. This 
idea can be expressed in the following variable form: 
 
𝑀𝑖(𝑢 + 𝑒𝑘 + 𝑒𝑝 + 𝑝𝑣)𝑖 − 𝑀𝑜(𝑢 + 𝑒𝑘 + 𝑒𝑝 + 𝑝𝑣)𝑜 − 𝑄 + 𝑊𝑠 = ∆𝐸 
 
The variables are defined as follows: 
 𝑀𝑖 = 𝑚𝑎𝑠𝑠 𝑖𝑛  
 𝑀𝑜 = 𝑚𝑎𝑠𝑠 𝑜𝑢𝑡  
 𝑢 = 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑒𝑛𝑒𝑟𝑔𝑦  
 𝑒𝑘 = 𝑘𝑖𝑛𝑒𝑡𝑖𝑐 𝑒𝑛𝑒𝑟𝑔𝑦  
 𝑒𝑝 = 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 𝑒𝑛𝑒𝑟𝑔𝑦  
 𝑝𝑣 = 𝑤𝑜𝑟𝑘 
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 𝑄 = 𝑒𝑛𝑒𝑟𝑔𝑦 𝑙𝑒𝑎𝑣𝑖𝑛𝑔 𝑡ℎ𝑒 𝑠𝑦𝑠𝑡𝑒𝑚 𝑎𝑠 ℎ𝑒𝑎𝑡  
 𝑊𝑠 = 𝑠ℎ𝑎𝑓𝑡 𝑤𝑜𝑟𝑘 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑒𝑑 𝑜𝑛 𝑡ℎ𝑒 𝑠𝑦𝑠𝑡𝑒𝑚 𝑏𝑦 𝑡ℎ𝑒 𝑠𝑢𝑟𝑟𝑜𝑢𝑛𝑑𝑖𝑛𝑔𝑠 
 Δ𝐸 = 𝑡𝑜𝑡𝑎𝑙 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑒𝑛𝑒𝑟𝑔𝑦 
 
This equation can be simplified if kinetic and potential energy are negligible. The following is the 
simplified form of the equation:   
 
∑ 𝑀ℎ 
𝑖𝑛𝑝𝑢𝑡
− ∑ 𝑀ℎ
𝑜𝑢𝑡𝑝𝑢𝑡
− 𝑄 + 𝑊𝑠 = ∆𝐸 
 
The variables are defined as follows: 
 𝑀 = 𝑚𝑎𝑠𝑠  
 ℎ = 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑒𝑛𝑒𝑟𝑔𝑦  
 𝑄 = ℎ𝑒𝑎𝑡 𝑒𝑛𝑒𝑟𝑔𝑦   
 𝑊𝑠 = 𝑠ℎ𝑎𝑓𝑡 𝑤𝑜𝑟𝑘  
 Δ𝐸 = 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑒𝑛𝑒𝑟𝑔𝑦  
 
Using this equation, it is possible to predict how much heat must be removed from or added to a 
system to achieve optimal conditions.  
Enthalpy can occur as a result of a temperature change, phase change, mixing, or reaction. 
For the purposes of this study, enthalpy as a result of a temperature change will be the focus. 
Sensible heat is defined as the energy transfer required to increase or decrease the temperature. 
This can be determined using the heat capacity at constant air pressure, cp. Specific heat capacity 
(or just specific heat) is a term used to describe cp on a per-unit-mass basis. Change in enthalpy 
cannot be determined without the specific heat capacity. The following equation can be used to 
determine change in enthalpy, ΔH: 
 
∆𝐻 = 𝑀𝑐𝑝∆𝑇 = 𝑀𝑐𝑝(𝑇2−𝑇1) 
 
 
Heat of reaction, ΔHrxn, is the energy released or absorbed during a reaction.  
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∆𝐻𝑟𝑥𝑛 = ∑ 𝑀ℎ
𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠
− ∑ 𝑀ℎ
𝑟𝑒𝑎𝑐𝑡𝑎𝑛𝑡𝑠
 
∆𝐻𝑟𝑥𝑛 = ∑ 𝑛ℎ
𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠
− ∑ 𝑛ℎ
𝑟𝑒𝑎𝑐𝑡𝑎𝑛𝑡𝑠
 
 
M or n involves the actual mass or moles involved in the reaction.  
An exothermic reaction occurs when the energy required to hold the atoms of the product 
together is less than the energy required to hold the reactants together. This results in the release 
of surplus energy, causing a negative value for ΔHrxn.  
Specific heat of reaction, Δhrxn, depends on the reactants and products as well as the 
temperature and pressure. For this reason, it is not possible to calculate all possible values for 
Δhrxn. Instead, Δhrxn can be calculated using the heats of combustion, Δhc. Δhc is the heat that 
evolves during a reaction of a substance with oxygen to yield oxidative products such as gaseous 
carbon dioxide, gaseous nitrogen, and liquid water.  
 
4.4.2 Heat Loss Calculations 
The information in the previous section was used to determine the cooling of the skin / 
actual change in temperate of the skin during standard application of the Chlorhexidine skin 
preparation stick.   
The following assumptions can be made: 
1. Steady state system 
2. ∆𝐸 =  0 
The following equation is used to perform the calculations:  
𝑚1∆ℎ𝑣 =  𝑚2𝑐𝑝∆𝑇  
The variables are defined as followed:  
𝑚1 = 𝑚𝑎𝑠𝑠 𝑒𝑣𝑎𝑝𝑜𝑟𝑎𝑡𝑒𝑑 𝑜𝑓 𝐼𝑃𝐴 
Δℎ𝑣 = 𝑙𝑎𝑡𝑒𝑛𝑡 ℎ𝑒𝑎𝑡 𝑜𝑓 𝐼𝑃𝐴 
𝑚2 = 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑠𝑘𝑖𝑛  
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𝑐𝑝 = 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 ℎ𝑒𝑎𝑡 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 𝑜𝑓 𝑠𝑘𝑖𝑛 
Δ𝑇 = 𝑇1 − 𝑇2  = 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑡𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒 (𝑏𝑒𝑓𝑜𝑟𝑒 𝑎𝑛𝑑 𝑎𝑓𝑡𝑒𝑟 𝑡ℎ𝑒 𝑎𝑝𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐼𝑃𝐴)  
 
Some preliminary calculations were necessary to determine the values of the variables listed 
above. These calculations are shown below:  
𝑚1 = 𝜌1𝑣1 
𝜌1 = 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐼𝑃𝐴 = 786
𝑘𝑔
𝑚3
  (PubChem, 2019) 
𝑣1 = 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑎𝑛𝑡𝑖𝑠𝑒𝑝𝑡𝑖𝑐 = 1 𝑚𝐿 ∗
10−6𝑚3
1 𝑚𝐿
=  1 × 10−6 𝑚3 
 
Above, the team assumed that a 1ml volume sufficiently covered a 4 cm radius of application site. 
 
𝑚1 =  7.86 × 10
−4𝑘𝑔 = 0.786 𝑔  
 
Δℎ𝑣 = 44.8
𝑘𝐽
𝑚𝑜𝑙
×
1
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐼𝑃𝐴
= 44.8
𝑘𝐽
𝑚𝑜𝑙
×
1
60.0950
𝑔
𝑚𝑜𝑙
= 0.745
𝑘𝐽
𝑔
 
Δℎ𝑣 =  745
𝐽
𝑔
  (NIST, 2018)  
 
 
𝑚2 = 𝜌2 𝐴2  
 
Typically, at the University of Massachusetts Medical School, the antiseptic is applied in an 
outward circular motion to create a radius of about 4 cm. Thus, this is the value that the team 
used to calculate the area of the skin below:  
 
𝜌2 = 𝑠𝑘𝑖𝑛 𝑚𝑎𝑠𝑠 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 = 1.02
𝑔
𝑐𝑚3
 (𝐿𝑖𝑎𝑛𝑔, 2010) 
𝐴2 =  𝑎𝑟𝑒𝑎 𝑜𝑓 𝑠𝑘𝑖𝑛 = 𝜋(𝑟𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑠𝑘𝑖𝑛  𝑏𝑒𝑖𝑛𝑔 𝑝𝑟𝑒𝑝𝑝𝑒𝑑)
2 = 𝜋(4𝑐𝑚)2 = 50.265 𝑐𝑚2  
 𝑚2 = (1.02
𝑔
𝑐𝑚2
) (50.265 𝑐𝑚2) = 51.27 𝑔  
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𝑐𝑝 = 4.186
𝐽
𝑔℃
 (𝐵𝑒𝑟𝑔𝑚𝑎𝑛, 2011)  
𝑇1 = 35.02℃ (𝐵𝑖𝑒𝑟𝑚𝑎𝑛, 1936) 
𝑇2 = ?  
 
The following calculation was performed to determine the change in temperature: 
 
𝑚1∆ℎ𝑣 =  𝑚2𝑐𝑝∆𝑇 
(0.786 𝑔) (745
𝐽
𝑔
) = (51.27 𝑔)(4.186
𝐽
𝑔℃
)(35.02℃ − 𝑇2) 
𝑇2 = 32.29℃ ∴ ∆𝑇 = 2.73℃ 
 
4.4.3 Heat of Mixing Calculations 
Once the team calculated the heat loss on the skin caused by the application of the 
Chlorhexidine and Isopropyl alcohol solution, exothermic reactions were then further considered. 
The team calculated the necessary amounts of water and solvent for three different reactions to 
raise the temperature of the antiseptic solution to 40°C. After further discussion, the team decided 
to consider three reactions of salt in water, rather than those mentioned in section 4.3.2.1. The 
three salt and water reactions considered were lithium bromide and water, copper chloride and 
water, and lithium chloride and water. The following assumptions were made:  
1. There is 100% efficiency of heat transfer between water, 70% isopropyl alcohol, and the 
given salt. 
2. Chlorhexidine’s effects are negligible. 
The first equation used for this calculation is:  
𝑄𝐻2𝑂 = 𝑄IPA , 𝑤ℎ𝑒𝑟𝑒 𝑄 = 𝑒𝑛𝑒𝑟𝑔𝑦 = 𝑚𝑐𝑝Δ𝑇 
Since the applicator contains 70% isopropyl alcohol, QIPA was calculated assuming the solution to 
be 30% water and 70% isopropyl alcohol:  
𝑄IPA = 0.3(𝑚𝑐𝑝Δ𝑇)𝐻2𝑂
+ 0.7(𝑚𝑐𝑝Δ𝑇)IPA 
The values used for this calculation are shown in Table X below.  
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Table X. Properties of Water and Isopropyl Alcohol  
 Water Isopropyl Alcohol (IPA) 
Density (g/mL) 1 0.785 
Volume (mL) 10.5 10.5 
Specific Heat (J/molK) 75.34 161.2 
Change in Temp. (K) 2.73 2.73 
 
The calculation is performed below: 
 
𝑄𝐼𝑃𝐴 = [(0.3) (
1𝑔
𝑚𝐿
) (10.5 𝑚𝐿) (
1𝑚𝑜𝑙
18.02 𝑔
) (75.34
𝐽
𝑚𝑜𝑙 ∗ 𝐾
) (18°𝐶)]
+ [(0.7) (0.755
𝑔
𝑚𝐿
) (10.5 𝑚𝐿) (
1𝑚𝑜𝑙
18.02 𝑔
) (161.2
𝐽
𝑚𝑜𝑙 ∗ 𝐾
) (18°𝐶)] 
 
𝑄𝐼𝑃𝐴 = 237.1 𝐽 + 893.5 𝐽 = 1130.6 𝐽 
 
Because energy is neither created nor destroyed, QIPA can be set equal to Q of the water needed 
for the exothermic reaction to take place:  
 
𝑚𝐻2𝑂 ∗ 𝐶𝑝𝐻2𝑂
∗ Δ𝑇 = 1130.6 𝐽 ∴ 𝑚𝐻2𝑂 ∗ 75.34
𝐽
𝑚𝑜𝑙 ∗ 𝐾
∗ 18𝐾 − 1130.6 𝐽  
 
In the equation above, delta T of 18 K is the difference in temperature regarding the temperature 
of Chlorhexidine we are attempting to achieve. The team determined that the target temperature 
of the solution is 40°C, which would be an 18°C increase from where it currently sits at room 
temperature, 22 C. All temperatures were then converted to Kelvin for the calculations.  Solving 
for the moles of H2O, and multiplying by water’s molar weight of 18.02 g/mol, the required 
amount of water for an exothermic reaction is:  
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𝑚𝐻2𝑂 = 0.834 𝑚𝑜𝑙 ∗ 18.02
𝑔
𝑚𝑜𝑙
= 15𝑔 𝑜𝑓 𝐻2𝑂 
 
From here, each of the three chosen reactions were analyzed individually in order to determine 
the quantity of salt required.  
 
Lithium Bromide 
The first reaction considered was lithium bromide in water. To determine how much lithium 
bromide is necessary to heat the applicator solution, the heat of mixing was first determined to 
be:  
Δ𝐻𝐿𝑖𝐵𝑟 = −8127
𝐽
𝑚𝑜𝑙
 (𝐴𝑝𝑒𝑙𝑏𝑙𝑎𝑡, 1986) 
 
The number of moles of LiBr needed were then calculated using the following equation:  
 
 
Multiplying this value by the molar mass of LiBr, the mass of LiBr was determined:  
 
Copper Chloride  
The second reaction considered was copper chloride in water. To determine how much copper 
chloride is necessary to heat the applicator solution, the same procedure was followed as for 
lithium bromide above.  
Δ𝐻𝐶𝑢𝐶𝑙2 = −51.78
𝑘𝐽
𝑚𝑜𝑙
 (𝑉𝑎𝑛𝑑𝑦𝑠ℎ𝑒𝑣, 2003) 
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The number of moles of CuCl2 needed were then calculated using the following equation: 
 
Multiplying this value by the molar mass of CuCl2, the mass of CuCl2 was determined:  
 
Lithium Chloride 
The final reaction considered was lithium chloride (LiCl) in water. To determine how much LiCl 
is necessary to heat the applicator solution, the same procedure was followed as for lithium 
bromide and copper chloride above.  
Δ𝐻𝐿𝑖𝐶𝑙 = −37.1
𝑘𝐽
𝑚𝑜𝑙
 (𝐴𝑝𝑒𝑙𝑏𝑙𝑎𝑡, 1984)  
 
The number of moles of LiCl needed were then calculated using the following equation: 
 
 
Multiplying this value by the molar mass of LiCl, the mass of LiCl was determined:  
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4.4.4 Proposed Designs  
The following sections will discuss the first few design iterations that the team created.  
These were preliminary designs, which were eventually ruled out.  
 
4.4.4.1 Dual Chamber 
A dual chamber design would allow for a water-activated exothermic reaction to occur. 
The antiseptic application would be comprised of two chambers that are separated by a C-slide 
plastic cover slip that resembles a C-slide plastic webcam cover that is used to protect webcam 
privacy (Figure IV). The first chamber (toward the end of the applicator) would contain the 
exothermic salt that is separated from the antiseptic solution by a thin impermeable membrane and 
the glass ampoule containing the antiseptic solution. The bottom of the applicator would resemble 
a PTFE/silicone vial septum that can be punctured by a needle to introduce water to the salt 
chamber. Upon activation of the exothermic reaction, adequate heat transfer would occur through 
the impermeable membrane and glass ampoule to warm the antiseptic solution. Once warm 
(determined by an indicator). The C-slide cover slip can be opened to allow the warmed antiseptic 
solution to transfer into the second chamber. In the second chamber, the two plastic wings on the 
side of the applicator would be squeezed to break the glass and expel the warm antiseptic solution 
through the cotton pledget containing orange dye and then the foam sponge.  
Some of the advantages of this design is that the exothermic reaction will not be in direct 
contact with the antiseptic solution as there are two protective barriers separation the two. The two 
chambers allow for the exothermic reaction to warm the antiseptic solutions without interfering 
with the breaking of the glass ampoule. However, the disadvantages include the following: 
 There are additional resources (i.e. sterile water, sterile syringe, and sterile needle) that 
required to activate the exothermic reaction. This is an entirely new process that will 
require additional supplies, time, and procedure to be executed. 
 It is crucial that the C-slide plastic cover slip maintains its functionality throughout 
transportation, storage, and preparation procedures. If the cover slip loses its functionality 
due to bending or excessive sliding, it is possible that the glass ampoule will remain in the 
first chamber with no route of transport to the second chamber. 
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Figure IV. Illustration of dual chamber design 
 
4.4.4.2 Internal Tube 
An internal tube (containing the exothermic reaction) placed inside the glass ampoule 
(containing the antiseptic) would offer the best heat transfer to the solution because there is only 
one layer separating the reaction from the chlorhexidine solution (Figure V). The reaction tube 
would be made of plastic to ensure it does not break and mix with the antiseptic solution. To initiate 
the exothermic reaction, the reaction tube would contain the reactant and water separated by a 
breakable membrane. The membrane would be broken by shaking the tube vigorously. The 
dimensions of the original housing would need to change to accommodate the inner reaction tube. 
The complications of this design idea include manufacturing and ensuring proper breakage of the 
inner membrane without breaking the glass ampoule.  
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Figure V. Illustration of internal tube design. 
 
4.4.4.3 Reusable Sleeve 
The idea for the reusable sleeve prototype came from an environmentally friendly 
standpoint. The exothermic reaction would occur in a separate chamber from the application stick. 
While the reaction is producing heat, the user would slide on the chamber sleeve which would 
encase the long portion of the application stick (Figure VI). The heat would be transferred from 
the reaction, through the sleeve material, through the air in the tube and finally to the glass 
containing the chlorhexidine solution. This design would not change the existing mechanism and 
could be made to fit all applicator sizes, therefore eliminating the production of excess disposables. 
Once the reaction is completed, only the reactants would need to be changed while the housing 
could be kept and reused. The complications with this design come with sterilization and adequate 
heat transfer. For the sleeve to be reused, there must be a sterilization component between uses. 
Also, the mechanism of how to mix water with the reactant is unclear if the sleeve is enclosed. 
This design idea was ruled out because of the limited heat transfer between multiple layers of 
materials.  
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Figure VI. Illustration of reusable sleeve design.  
 
4.4.5 Final Design  
The final design that was selected features some components from previous design 
iterations that were discussed. This option will feature several chambers that will keep the various 
materials/components of the device separated until it is ready for use (Figure VII). The bottom-
most chamber will hold the amount of water necessary to initiate the exothermic reaction. A pull 
tab will be separating this chamber from the chamber above, which will contain the salts necessary 
for the exothermic reaction. Once the tab has been removed, the water will mix with the salts, 
initiating the exothermic reaction. This will allow heat will transfer from the second most chamber 
(where the salts were originally stored) through the material containing the isopropyl alcohol 
solution. Ideally, the exothermic reaction will warm the third chamber filled with isopropyl alcohol 
to the desired temperature for a certain amount of time. Once the antiseptic has been sufficiently 
warmed, a second pull tab can be removed. The removal of this tab will cause the antiseptic to 
flow through the orange dye above it and proceed through the sponge for final application to the 
patient skin. 
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Figure VII. Illustration of final design.  
 
4.5 Initial Testing 
In order to aid redesign of the ChloraPrepTM applicator, the team executed various initial 
self-testing protocols in which each team member served as an experimental test subject. The 
primary objective of this protocol was to record skin temperature before and after application 
of ChloraPrepTM antiseptic solution at room temperature and after being warmed to 37-40°C. The 
secondary objective was to relate the temperature data obtained from the protocol to the theoretical 
heat loss calculations. In addition, it also allowed the team to qualitatively feel if there was a 
significant difference in comfort when the solution was warmed prior to application on the skin.  
To limit the quantity of experimental variables, each protocol was completed in one-sitting 
under the same conditions (e.g. room temperature and humidity, location of application). The 
antiseptic solution was applied on the inside of the upper left arm with at an application site with 
an approximate 4-centimeter radius. 
 
4.5.1 Initial Self-Testing  
         The first protocol that the team executed required the application of the ChloraPrepTM 
solution at room temperature. This test was performed in the GH007 MQP Lab and allowed the 
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team to qualitatively and quantitatively determine the heat loss of the skin when the solution was 
applied.  
 
4.5.1.1 Initial Self-Testing Protocol  
Objective:  
 Record quantitative data regarding temperature of skin before and after application of 
ChloraPrepTM antiseptic solution 
 Relate antiseptic application to theoretical heat loss calculations 
Materials: 
 Etekcity Laser Grip 774 infrared temperature gun 
 4 ChloraPrepTM 10.5 mL antiseptic applicators 
 Thermometer and humidity detector 
 Test subjects (ourselves)  
Procedure: The following describes the protocol that will be used to test the ChloraPrepTM 
antiseptic on test subjects.  
1. Record ambient room temperature and humidity.  
2. Record the initial temperature of the testing area using the non-contact digital infrared 
thermometer.  
a. Following the instructions of this device, the thermometer should be held at a 
distance approximately 36 cm away from the surface of interest.  
3. Open ChloraPrepTM antiseptic applicator and follow directions for application.  
4. Apply to inside of bicep in a circular motion approximately 4 cm diameter for 30 seconds.  
5. Record temperature using digital infrared thermometer at time 0s, 30s, 60s, 120s, 180s. 
Follow the same procedure as stated in Step 2a.  
6. Repeat on each team member.  
 
4.5.1.2 Initial Self Testing Results  
Table XI below displays the skin surface temperature at various times. The “-30 seconds” 
time stamp refers to the initial skin temperature prior to antiseptic solution. The “0 seconds” time 
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stamp refers to the skin’s temperature immediately after the antiseptic solution was applied to the 
skin. The remainder of the time stamps refer to skin’s temperature while the antiseptic solution 
was drying on the skin. The skin’s temperature was recorded for a total of 3 minutes, which is the 
recommended drying time for antiseptic solution applied on hairless skin. When analyzing the line 
graph (Figure VIII) it is evident that the largest drop in skin temperature was immediately after the 
completion of the antiseptic application with the skin’s temperature dropping an average of 3.8 
°C. This result reinforced the initial client problem statement the team received from Dr. Hussain 
as he stated that, “Patients are discomforted by the sudden chill of the antiseptic solution upon 
initial stages of application”.  
 
Table XI. Average Change in Skin Temperature after Application of Antiseptic at Room Temperature 
Test 
Subject 
Time 
(s) 
Skin Surface 
Temperature 
(°C) 
Average Change in Skin 
Temperature (Directly 
After Application) (°C) 
Average Change in Skin 
Temperature (Overall) (°C) 
A 
-30 31.4 
3.8 2.4 
0 27.6 
30 26.8 
60 27.2 
120 28.3 
180 29.0 
B 
-30 32.1 
2.9 3.1 
0 29.2 
30 28.0 
60 27.7 
120 29.4 
180 32.1 
C 
-30 32.5 
4.5 2.9 
0 28.0 
30 27.5 
60 29.0 
120 29.2 
180 32.5 
D 
-30 29.0 
4.0 2.9 
0 25.0 
30 27.0 
60 26.3 
120 26.0 
180 26.1 
Average Change in Skin Temperature (Directly After Application) (°C) 3.8 
Average Change in Skin Temperature (Overall) (°C) 2.8 
Note: the data in Table XI is the average of three testing trials 
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Figure VIII. Average change in skin temperature after the application of antiseptic at room temperature 
from three testing trails per test subject (n = 3). Skin temperature was measured for a duration of 3 
minutes. The”-30” second time stamp represents initial skin temperature 30 seconds prior to application 
of ChloraPrepTM. The standard deviation at time zero is ±0.85°C. 
 
4.5.2 ChloraPrepTM Warming Testing  
Following the initial testing performed, the team then tested the application of warmed 
ChloraPrepTM solution. This test was performed for the team to determine if applying warmed 
ChloraPrepTM solution would result in a more pleasant application experience.  
 
4.5.2.1 ChloraPrepTM Warming Testing Protocol  
Objective: 
 To determine if warming the ChloraPrepTM applicator prior to application would result in 
a smaller decrease in temperature of the skin. 
Materials:  
 4 ChloraPrepTM Applicators 
 Water 
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 Hot water bath 
 Etekcity Laser Grip 774 infrared temperature gun 
 Thermometer and humidity detector 
 Test subjects 
Procedure: 
1. Place sticks in a water bath of 37 °C for approximately 1 hour prior to the start of testing. 
2. Record the initial temperature of the testing area using the non-contact digital infrared 
thermometer.  
3. Following the instructions of this device, the thermometer should be held at a distance 
approximately 36 cm away from the surface of interest.  
4. Open ChloraPrepTM antiseptic applicator and follow directions for application.  
5. Apply to inside of bicep in a circular motion approximately 4 cm diameter for 30 seconds.  
6. Record temperature using digital infrared thermometer at time 0s, 30s, 60s, 120s, 180s. 
Follow the same procedure as stated in Step 2a.  
7. Repeat on each team member.  
 
4.5.2.2 ChloraPrepTM Warming Testing Results 
Unfortunately, this was a failed experiment where no real results were obtained. While 
the ChloraPrepTM applicators were warming in the water bath, the liquid from within them began 
to leak around the twenty-two-minute mark. The team believes this leakage was due to the sponge 
portion of the applicator getting wet. Although the sponges were wrapped in parafilm, a water-
tight seal was not formed. Once the applicators began to leak, they became unusable for accurate 
testing results (Figure IX).  
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Figure IX. Image of the ChloraPrepTM applicators in a water bath at 37°C. After 
22 minutes in the water bath, the applicators began to leak orange coloring 
from their sponge applicator. 
 
4.5.3 Alcohol Warming Testing  
 As a result of the failed ChloraPrepTM warming testing, the team modified their plan and 
tested solely warmed 70% IPA. Without the applicators this experiment did not completely 
simulate the application process during a standard procedure, but it still allowed the team to 
observe the effects of warming the antiseptic.  
 
4.5.3.1 Alcohol Warming Testing Procedure  
Objective: 
 Record quantitative data regarding the temperature of the skin before and after the 
application of warmed 70% isopropyl alcohol  
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Materials:  
 70% Isopropyl Alcohol 
 10mL Test tube  
 Hot plate  
 Beaker  
 Stir bar 
 Etekcity Laser Grip 774 Infrared Temperature Gun 
 Thermometer and Humidity Detector 
 Test Subjects (ourselves)  
Procedure:  
1. Place a test tube full of 70% Isopropyl alcohol in a beaker full of water on a hot plate 
2. Heat until the Isopropyl alcohol reaches 35°C 
3. Record the initial temperature of the testing area using the non-contact digital infrared 
thermometer.  
4. Following the instructions of this device, the thermometer should be held at a distance 
approximately 36 cm away from the surface of interest.  
5. Wet a paper towel with the warmed Isopropyl alcohol 
6. Apply to inside of forearm in a circular motion approximately 4 cm diameter for 30 
seconds.  
7. Record temperature using digital infrared thermometer at time 0s, 30s, 60s, 120s, 180s. 
Follow the same procedure as stated in Step 2a.  
8. Repeat on each team member.  
9. Repeat entire testing protocol at 40°C.  
 
4.5.3.2 Alcohol Warming Testing Results 
 As outlined in the procedure from the previous section, IPA was warmed to 35°C and 
40°C and applied to the inner forearm of the test subjects. This testing was designed to guide the 
team in determining a target temperature for the antiseptic that felt most comfortable on the skin. 
The raw data from this testing can be seen in Tables XII and XIII below. In these tables, “-30 
seconds” symbolizes the initial skin temperature prior to antiseptic solution. The “0 seconds” time 
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stamp refers to the skin’s temperature immediately after the warm isopropyl alcohol was applied. 
The remainder of the recorded times refer to skin’s temperature while the isopropyl alcohol was 
drying on the skin. The skin’s temperature was recorded for a total of 3 minutes, which is the 
recommended drying time for antiseptic solution applied on hairless skin.   
 The temperature loss at application can best be observed in the graphical representation 
of the data shown in Figures X and XI. At 35°C, the average temperature loss at application for 
the team as a whole was 1.63°C. At 40°C, the average temperature loss was 1.70°C. For the 
application at both 35°C and 40°C, the largest drop in skin temperature occurs immediately after 
the application of the IPA. It is important to notes, however, that the overall decrease in 
temperature of the warmed IPA is significantly less than the testing with room temperature IPA. 
This shows that warming of isopropyl alcohol does in fact decrease the skin temperature drop felt 
by patients.  
Table XII. Average Change in Skin Temperature after Application of Antiseptic at 35°C 
Test 
Subject 
Time 
(s) 
Skin Surface 
Temperature 
(°C) 
Average Change in Skin 
Temperature (Directly 
After Application) (°C) 
Average Change in Skin 
Temperature (Overall) (°C) 
A 
-30 32.4 
2.8 0.4 
0 29.6 
30 27.9 
60 28.4 
120 29.3 
180 30.0 
B 
-30 32.0 
2.0 0.4 
0 30.0 
30 28.9 
60 29.0 
120 29.9 
180 29.9 
C 
-30 31.6 
1.3 0.3 
0 30.3 
30 28.9 
60 29.0 
120 29.9 
180 29.9 
D 
-30 28.9 
0.4 0.1 
0 28.5 
30 27.5 
60 27.4 
120 28.0 
180 28.1 
Average Change in Skin Temperature (Directly After Application) (°C) 2.5 
Average Change in Skin Temperature (Overall) (°C) 1.2 
Note: the data in Table XI is the average of three testing trials 
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Figure X. Average change in skin temperature after the application of antiseptic at 35°C from three testing 
trails per test subject (n = 3). Skin temperature was measured for a duration of 3 minutes. The”-30” 
second time stamp represents initial skin temperature 30 seconds prior to application of 
ChloraPrepTM. The standard deviation at time zero is ±1.02°C. 
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Table XIII. Average Change in Skin Temperature after Application of Antiseptic at 40°C 
Test 
Subject 
Time 
(s) 
Skin Surface 
Temperature 
(°C) 
Average Change in Skin 
Temperature (Directly 
After Application) (°C) 
Average Change in Skin 
Temperature (Overall) (°C) 
A 
-30 31.7 
2.6 0.7 
0 29.1 
30 30.1 
60 30.7 
120 31.0 
180 31.0 
B 
-30 31.4 
2.8 1.9 
0 28.6 
30 28.9 
60 29.0 
120 29.3 
180 29.5 
C 
-30 32.4 
3.2 0.7 
0 29.2 
30 29.7 
60 30.4 
120 30.9 
180 31.1 
D 
-30 31.8 
1.2 1.0 
0 30.6 
30 30.8 
60 30.8 
120 30.6 
180 30.8 
Average Change in Skin Temperature (Directly After Application) (°C) 2.5 
Average Change in Skin Temperature (Overall) (°C) 1.2 
Note: the data in Table XII is the average of three testing trials 
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Figure XI. Average change in skin temperature after the application of antiseptic at 40°C from three 
testing trails per test subject (n = 3). Skin temperature was measured for a duration of 3 minutes. The  
”-30” second time stamp represents initial skin temperature 30 seconds prior to application of 
ChloraPrepTM. The standard deviation at time zero is ±0.51°C.  
 
A one-way ANOVA test was performed comparing the temperature changes at time zero for 
the unwarmed, 30°C, and 40°C self-testing trials. The p-value corresponding to the one-way 
ANOVA (α = 0.05) is less than 0.05 which suggests that one or more treatments are significantly 
different. A post-hoc test will identify which pairs of treatments are significantly different from 
each other. Tukey’s Honest Significant Difference (HSD) test is based on the studentized range 
distribution. With three groups and 9 degrees of freedom, the critical values of 
the studentized range Q statistic are compared resulting in a significant difference 
between unwarmed vs. 35°C and unwarmed vs. 40°C with Tukey HSD p-values 0.0012 and 
0.0014 respectively. There is no significant difference between the 35°C and 40°C pair.   
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5 Design Verification  
Design verification is a fundamental aspect of a design process. This chapter will focus on the 
verification completed for the team’s final prototype. This will include the raw results from all 
testing completed with the final design. These tests include temperature changes during LiCl and 
water mixing, temperature changes of IPA from LiCl and water, and a second set of self-testing 
on the team’s skin. The importance and meaning of these results will be discussed further on in 
the paper in the “Analysis and Discussion” section.  
 
5.1 Lithium Chloride and Water Testing 
Once the team decided to move forward with a LiCl and water warming mechanism, the 
first testing completed was to determine the amount of LiCl needed to warm the Chlorhexidine 
solution. The team began the testing with the amount of LiCl and water calculated previously in 
section 4.4.3 – 0.0898 g and 7 mL, respectively. However, more tests were also completed that 
used 7mL of water and increasing amounts of LiCl – 0.19 g, 0.5 g, 1 g, and finally 2 g. These were 
completed in order to find the correct ratio of LiCl to water for the temperature increase that was 
desired.  
For each trial, the respective amount of LiCl was placed in a small beaker on a stir plate. 
The 7 mL of water was then added, and the temperature of the mixture was recorded for up to 120 
seconds. The summarized results of the experiments can be seen in the Table XIV below: 
 
Table XIV: Resulting Temperatures of Varying Amounts of LiCl in 7 mL of Water 
Amount of LiCl in 7 mL of Water (g) Largest Change in Temperature (°C) 
0.0898 1.5 
0.1900 0.5 
0.5000 4.5 
1.000 10 
2.000 23 
2.000 17 
 
As seen in the table above, 2.000 g of LiCl in 7 mL of water was performed in duplicate. This 
is because only the initial 2.000 g test gave us a large enough increase in temperature for us to 
perform testing. The team’s conclusion and analysis of these results will be discussed in section 7, 
“Analysis and Discussion”.  
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5.2 Lithium Chloride, Water, and IPA Testing 
 Following the testing discussed in section 5.1, the team then decided to test the change in 
temperature of Isopropyl Alcohol during the mixing of LiCl and water. For this test, 7 mL of water 
and 3.000g of LiCl were placed in a graduated cylinder on a stir plate. A conical tube filled with 
10.5 mL of Isopropyl alcohol was then placed within the graduated cylinder. Two thermometers 
were used to measure the temperature of the LiCl and water mixing, as well as the isopropyl 
alcohol over a 120 second period.  
From three separate trials, the average highest temperature that the IPA reached was 40°C.  
These average results from the three testing trials can be seen in the Figure XII below. 
 
 
Figure XII. Average Results from 3 Testing Trials of IPA and Heat of Mixing Reaction 
 
 
5.3 Antimicrobial Testing 
Quantitative suspension antimicrobial testing was performed following the EN 1276 
standard in order to ensure that ChloraPrep is still fully effective as a disinfectant even after being 
heated. The protocol for this standard can be found in Appendix D. The team performed 3 
replicates for their testing. For each replicate, there were three groups: a sterile plate with culture 
broth, a growth place with 150 colony-forming units (CFU) of Staphylococcus Aureus, and an 
experimental plate 1.5 x 108 CFU of Staphylococcus Aureus suspended in Chlorhexidine 
Gluconate in IPA. The EN 1276 standard states that there must be a 4-log reduction in bacterial 
count after a 24-hour incubation period in order to be effective. The team had 6-log reduction for 
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all three replicates of plates with warmed chlorhexidine gluconate, meaning that the standard was 
met. This can be observed visually in Figure XIII below.  
 
Figure XIII: Visual representation of antimicrobial testing results. Each plate is labeled with the name of its 
respective experimental group and the quantity of bacteria plated.  
 
5.5 Rapid Prototyping and 3D Prototype Evaluations 
Rapid prototyping is advantageous for design-based projects as research teams can conduct 
conceptual analyses, functionality testing, and design verification with 3D-printed models in a 
cost-effective and time-efficient manner. Over the course of the prototyping timeline, the team 
created a total of 3 prototypes using CAD modeling in SolidWorks, which also served as the 
modeling files for 3D printing. In the subsections below, each prototype design will be explained 
and evaluated. 
After consulting with Dr. Erica Stults, the prototypes were printed using WPI’s FormLabs 
Form 2 Stereolithography (SLA) 3D printer, which uses a liquid resin that is cured with a 405 nm 
violet laser. The primary benefit of this printer to is its ability to print small, intricate features with 
a smooth surface finish.  
 The main features the team wanted the devised prototypes to incorporate include the 
following: (a) a compartment to store 7 mL water, (b) compartment to store the ≥ 2g reactive salt, 
(c) a compartment to store 10mL antiseptic solution, (d) a barrier mechanism to separate the water 
from the reactive salt, (e) barrier mechanism to separate the salt-water reaction from the antiseptic, 
and (f) a barrier mechanism to separate the antiseptic from the dye pledget and application sponge. 
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Such features would allow the following processes to be executed when a patient is being prepared 
for procedure that requires antiseptic application: 
When the rubber pull tab is released outward, the opening of the water-storing 
compartment is exposed and allow water to expel into the compartment containing the reactive 
salt. The heat that is generated from the thermogenic reaction, when the water meets the salt, will 
warm the antiseptic solution contained in the inner tube. Once the antiseptic solution is warm, the 
second pull tab can be released to allow the warm antiseptic to dispel into the dye pledget and the 
application sponge.  
 
5.5.1 Prototype 1 
The first prototype the team created consists of 2 concentric tubes: an inner tube to store 
the antiseptic and an outer tube to store the salt (Figure XIV and XV). The semi-circle openings 
on the ends of the tube are designed to hold the rubber tabs, which would serve as a physical barrier 
that separates the water from the salt and the antiseptic from the application sponge (not shown).  
 
Figure XIV. Isometric view of prototype 1 
 
 
Figure XV. Front view of prototype 1 
  
To generate a high-level tangible model of the tube, the team did not include the 
compartment to store water and the region to adhere the application sponge. This prototype served 
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as a baseline prototype that the team would gradually modify to improve functionality. Favorable 
and unfavorable design features are described in Table XV below. 
 
Table XV. Prototype 1 Evaluation 
Prototype 1 
Material: Rigid White 
Cost: $6.09 
Favorable Features 
 
 The prototype is ergonomically designed in 
that it is easy to hold with a comfortable grip. 
 The dimensions of the prototype yield a thin, 
cylindrical tube that has a streamlined profile. 
Unfavorable Features 
 
 The outer tube’s wall thickness of 1mm is 
fragile and too thin. When removing the 
supports, the one of the ends of the tube broke 
off (Figure XIII). 
 The semi-circle slots do not allow for the 
rubber tabs to be inserted and pulled out 
securely while preventing any water from 
leaking out of the device. 
 
 
5.5.2 Prototype 2 
Based on the evaluation of the first prototype, the team devised a second prototype shortly 
after. This prototype follows a design scheme that is similar to prototype 1 in that is features 
compartments for each material and two thin slots to separate the contents of the compartments 
(Figure XVI). 
 
Figure XVI. Isometric View of Prototype 2 
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While evaluating the first prototype, the team noted that the fragility of the design was 
partially caused by the high length-to-width ratio. To better balance the tube’s dimensions, the 
team opted for a square-shaped tube because with the same dimensions (length and width) can 
store more volume. Additionally, the outer wall thickness was doubled (from 1mm to 2mm) to 
increase the strength of the walls.  
In prototype 1, where this system was not included, the pull tabs were easily bent and 
shifted and that encouraged undesired water leakage from the device. To resolve this design issue, 
the team incorporated a “ledge/shelf” system at the slot separating the water and salt compartments 
to allow the pull tab to rest between the rigid surfaces. Favorable and unfavorable design features 
are described in Table XVI below. 
 
 
Table XVI. Prototype 2 Evaluation 
Prototype 2 
Material: Rigid Clear 
Cost: $10.90 
Favorable Features 
 
 The prototype is ergonomically designed in 
that it is easy to hold with a comfortable grip.  
 The design includes a shelf system that will 
add stability to the pull tab and reduced 
unwanted movement.  
 The tube design is stronger as the dimension 
ratios are more balanced. 
Unfavorable Features 
 
 Another pull tab is needed at the top of the 
tube to contain the antiseptic solution. 
 The inner tube is too short in length, which 
will result in inconsistent warming of 
antiseptic solution. 
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6 Final Design and Validation  
Throughout the course of this project, the team has brainstormed, developed, and carried out 
various testing procedures in order to create a successful final design. A large portion of this project 
was also dedicated to brainstorming and executing various design solutions. The purpose of this 
report section is to give an overview of how the team’s initial objectives were met with the final 
design. In addition, the team will briefly discuss industry standards relevant for the design, as well 
as various societal impacts the design might make.  
 
6.1 Final Design Overview 
       This section will briefly outline the steps that were taken in order to achieve the final design. 
This will include an overview of the objectives the team was aiming to reach, and whether they 
were. Additionally, the team’s experimental and data analysis methods will be summarized.  
 
6.1.1 Final Design Objectives  
       When beginning this project, the team had five main objectives to achieve. The first objective 
was to develop a cost-effective device for pre-warming of antiseptics solutions. The team believes 
that this objective was ultimately achieved. With the use of a LiCl and water mixture, the 
ChloraPrepTM solution temperature was raised an average of 18 °C prior to application. 100 g of 
LiCl, enough for 50 applicators, can be bought for under $80 – meaning that the only additional 
cost to this device is under $2. Objective two was to improve overall patient experience. Although 
this objective cannot be quantified, the team believes that the successful warming of the 
ChloraPrepTM solution will make patients more comfortable. The third objective was to create a 
universal design that could be applied to comparable skin preparation applicators on the market. 
Although the safety of warming different skin preparation solutions would need to be ensured, the 
team also believes this objective was achieved. With our three-chamber final design, the salt 
solution (LiCl and water) can remain constant. However, the inner chamber of the applicator can 
hold other types of disinfectants, as needed. The fourth objective was to ensure the safety of the 
patient and medical staff. Although antiseptic solutions can be flammable, the amount of LiCl and 
water used to heat the ChloraPrepTM only allows it to reach a maximum temperature of 40°C. We 
strongly believe this temperature is not high enough to put the patient or medical team in danger. 
The fifth objective was maintaining the original functionality of the device. Through antimicrobial 
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testing with the EN 1276 standard, the team was able to meet this objective and maintain a 6-log 
bacterial reduction, meaning that the device remained fully effective.  
 
6.1.2 Summary of Experimental Analysis  
        Overall, the team had two main groups of experimental methods: warming of the 
ChloraPrepTM solution and the effectiveness of a newly designed applicator. These two groups 
were initially tested independently, before being combined into one functioning device.  
         To begin the task of effectively warming ChloraPrepTM, the team had to complete 
background research pertaining to the effectiveness of mixing solutions to give off heat. Factors 
such as cost and safety helped the team narrow this down to three different mixing reactions. From 
here, the team completed a series of calculations in order to determine the amount of each salt 
required to produce the desired amount of heat (enough to raise the ChloraPrepTM to a maximum 
of 40°C). LiCl was then chosen by the team to be experimentally tested, due to its relatively low 
price and the small amount needed. Although these calculations provided the team with an 
effective estimate, there were assumptions that were made – such as no loss of heat to the air, and 
heat transfer through our desired final material rather than the materials we had access to in the 
lab. Therefore, obtaining experimental results was the next step. The team began by testing various 
amount of LiCl in water until it reached our desired temperature of 40°C. Adjustments in the 
amount of LiCl used were made, despite the fact that this left the team with a higher amount than 
originally calculated.  
Once the team determined that 2.00 g of LiCl in 7 mL of water was needed, the effects of 
this reaction on the temperature of IPA was tested. For these tests, LiCl and water were mixed in 
a graduated cylinder, and a conical tube of 10.5 mL of IPA was also placed in the graduated 
cylinder. The temperature of both solutions was measured over a period of about two minutes. 
The testing performed in the previous paragraph demonstrated to the team the difficulty of 
warming IPA to 40°C. Although the LiCl and water mixture temperature exceeded this amount, 
due to various factors such as heat escaping to the air or poor heat transfer, the alcohol was not 
warmed as the team hoped. Therefore, the team performed self-testing in order to determine the 
effects of applying IPA at 35°C to the skin rather than 40°C. The team felt that this was a much 
more attainable result that would still reduce or eliminate the chilling sensation currently induced 
by ChloraPrepTM application.  
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In addition to the warming testing, the team simultaneously designed and created applicator 
prototypes. The design process for these prototypes began with brainstorming, from which we 
chose a few designs to further develop. After various discussions, the team’s first attempted design 
was chosen, designed on SolidWorks, and rapid prototyped. After receiving the prototype, the 
team tested its capability to hold water and determined design changes to be made for the next 
version. From here, two more designs were prototyped and tested until the final design was created.  
 
6.2 Applicable Engineering Standards  
           As discussed previously in this report, there are various standards that are applicable to the 
team’s final design. The purpose of this section is to discuss whether these standards were met 
with our design, or if they must be incorporated into the design if the device were to be 
manufactured and marketed.  
       The first set of standards to be considered are AST Standards – specifically Standard of 
Practice II, III, and VIII. Standard of Practice II states that for pre-procedural skin preparation, 
healthcare facilities should use FDA-approved agents with immediate and persistent antimicrobial 
properties (AST Education and Professional Standard Committee, 2008). The team’s final design 
will continue to incorporate the same Chlorhexidine Gluconate and IPA solution as current 
ChloraPrepTM, which is FDA approved, and thus this standard is met by the new design. Standard 
III states that alcohol should not be used as a single agent for antiseptic purposes (AST Education 
and Professional Standards Committee, 2008). As previously mentioned, the Chlorhexidine 
Gluconate and IPA solution of the current ChloraPrepTM will be used within the new design, and 
therefore this standard is also met. The final standard, Standard of Practice VIII, however, is not 
met by the team’s design. This standard states that if a skin preparation solution is flammable, it 
must not be warmed, per manufacturer’s instructions (AST Education and Professional Standards 
Committee, 2008). Seeing as warming the ChloraPrepTM solution was one of the main objectives 
of this project, this standard was not met, and will continue to not be if it were to be manufactured 
and marketed. However, the team does not believe the level to which the solution is being warmed 
is harmful or will pose a threat to personal safety.  
         The next of standards to be considered are ISO standards. Standards of interest to the team 
are ISO 11737-2:2009, ISO 13485:2016, and ISO 15378:2017. In order for an ISO standard to be 
met, all activities must be completed within an ISO certified environment. None of the lab spaces 
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that were utilized for this project were ISO certified, and therefore, currently the team’s design 
does not meet these standards. However, in the future, if this device is manufactured in the future, 
it should be ensured that the manufacturing facility is ISO certified for these specific standards.  
      In order to be marketed and used in medical facilities, the team’s design must abide by current 
FDA regulations. Currently, antiseptic agents are regulated under the FDA’s Over-the-Counter 
Drug Products division (“Safety and Effectiveness”, 2017). These antiseptic agents must reduce 
transient microorganisms, possess a broad range of antimicrobial properties, be fast-acting with 
long-lasting activity, and not cause irritation to the skin. Seeing as ChloraPrepTM solution is 
currently FDA approved, by using the same solution, the team’s design in theory would also be 
FDA approved. However, because the team modified a pre-existing skin preparation applicator 
that contains chlorhexidine-gluconate, a New Drug Application will need to be submitted for FDA 
approval (“Safety and Effectiveness”, 2018). This is because in December 20, 2018, the FDA 
stated that chlorhexidine-gluconate and iodophors will not be general recognized as safe for use in 
antiseptics – individual approval is now required.  
               The final standards being considered are European Standards and Criteria. These 
standards confirm or reject that the redesigned device does not jeopardize the effectiveness of the 
antiseptic solution. ChloraPrepTM is currently compliant with standards EN 1040, EN 1275, EN 
13727, and EN 13624. Antimicrobial testing was completed for this project according to standard 
1276. However, all other applicable standards would need to be considered when manufacturing 
and marketing this device in the future.  
 
6.3 Impact of Final Design  
       It is desired that the team’s final design will someday be manufactured and marketed. With 
this, however, it is necessary to consider the impacts that the final design may have on the world. 
This is a design that will be in direct contact with both patients and healthcare professionals. In 
this section the team will briefly analyze the final design’s impact on daily economics, 
manufacturability, health and safety, and the environment.  
 
6.3.1 Economics  
        The goal of this project was to improve upon the current ChloraPrepTM design by reducing 
the chilling sensation that it causes when applied to the skin. Although the final design has not 
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undergone high-volume manufacturing with the team’s recommended final materials, its prototype 
has been successfully manufactured with the team’s resources. This involved utilizing the rapid 
prototyping, as well as other academic labs, on WPI’s campus.  
         The final design developed closely models the current ChloraPrepTM applicator on the 
market. Therefore, the team does not believe that the economic impact of their design will be large. 
The device is about the same size as the current applicator, so the team expects the amount of resin 
required to injection or blow mold the product to stay the same. The only additional cost for the 
new design is the LiCl, which can be purchased for as little as $80 per 100 grams (Sigma Aldrich, 
n.d.). For reference, the new design only utilizes about 2 grams per applicator, meaning that at this 
price point, each applicator will have an increased cost of no more than $2.00. Although there are 
economic factors to consider when taking this design from the lab to full utilization in the clinic, 
the team believes the additional cost does not outweigh the design’s benefits.  
 
6.3.2 Manufacturability and Sustainability 
       Although the team believes the project design can be manufactured, there are still concerns 
regarding manufacturability. Currently, ChloraPrepTM applicators are injection- or blow-molded. 
Although the new design is also able to be molded in this manner, injection molding can be quite 
costly if the product is not being produced in a large volume. In order to be cost efficient, high 
volume manufacturing will be required. In order to manufacture this device in a sustainable 
manner, it would be beneficial to create it using recycled resins and plastics for molding. This 
would hopefully cause a smaller environmental impact than the use of new resins. The new design 
will also require additional manufacturing steps that will involve either an operator adding LiCl 
and water to their respective chambers within the device, or some type of automated system to do 
so. Although manufacturing is viable at this point in the project, if it were to be continued, the cost 
and lead time of such a process must be considered.   
 
6.3.3 Ethical Concerns and Health and Safety Issues  
         It is imperative that the team consider the health and safety issues surrounding the device as 
its eventual intended use is in a medical/hospital setting on a frequent basis. Based on the research 
and data collected, the device that the team has design should pose no more risk than the current 
ChloraPrepTM sticks. Although the current ChloraPrepTM sticks bear a warning regarding 
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warming/heating of the device, the team has determined that the temperature to which the 
antiseptic is being warmed does not increase risk to the patient or user. The device does not reach 
a high enough temperature to pose risks of flammability or explosion. Furthermore, warming of 
the antiseptic solution does not affect its antimicrobial properties. Additionally, the solution will 
not reach a high enough temperature for thermal expansion to be a concern within ithe device.  
         Additional caution should be taken with the new device design to ensure that the mixture of 
LiCl and water does not mix with the antiseptic solution. The final design should incorporate a 
visual indicator (such as a color change) to show the user if the antiseptic mixes with the LiCl.  
         It is also important to consider ethics when introducing a new device into the market. It will 
be important that a patient’s level or manner of treatment is in no way dictated by the type of 
antiseptic device they elect to have used. Additionally, all patients should be given the choice to 
decide between traditional antiseptic and the team’s new warmed device, once it is on the market.  
 
6.3.4 Environmental Impact  
         It is essential to consider potential environmental impacts of a new product to ensure that 
damage is not occurring to the world. Currently, the project is still being run and explored on a 
small scale. However, if large-scale manufacturing and marketing is a goal in the future, their 
environmental impact must be considered. As far as benchtop lab testing is concerned, the team 
utilized items such as IPA, glass labware, and items such as hotplates – all of which are not 
regularly discarded or do not cause concern when discarded. In the future, considerations will 
include the disposal of the finished device due to the LiCl held in it. The new design cannot be 
disposed in the same manner as current ChloraPrepTM sticks due to this reason. It is necessary to 
keep LiCl out of drains, sewers, and waterways (“Safety Datasheet for LiCl Solution”, 2016). 
Additionally, it is advised that LiCl is dissolved in a combustible solvent or absorbed into a 
combustible material and burned by a chemical incinerator. Any empty containers that once held 
LiCl, such as the final project design, must also be triple rinsed prior to disposal (“Safety Datasheet 
for LiCl Solution”, 2016). Although there are ways in which to safely dispose of LiCl, before 
producing this product on a large scale, they must be determined and advised to all that utilize the 
design. If a safe disposal protocol is determined, the team’s design should have little negative 
impact on the environment.  
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6.3.5 Societal Impact and Political Ramification 
It is hoped that the new design will help patients feel more comfortable during medical 
procedures and willing to return for more in the future, and thus will have a positive societal 
impact. The team does not believe that there will be political ramification in the United States from 
this product. However, it is important to consider that any increase in price from standard antiseptic 
applicators may be too expensive for some patients in other communities to take advantage of. The 
team expects that in some other communities, the device will have a neutral impact rather than a 
positive one.  
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7 Discussion  
The goal of this chapter is to discuss the results presented in previous sections of this report. 
This will include a discussion of the warming results achieved by the new design. Additionally, 
the antimicrobial activity of the team’s design will be discussed and compared to that of the 
required standards and the current ChloraPrepTM applicator and solution. The team will also 
discuss limitations encountered during the course of the project, and how they were not critical to 
designing a successful product in the end.  
 
7.1 Final Design 
The final design, as seen in Figure XVII, is comprised of one solid part made of resin with 
multiple rubber parts. The open end has the function of holding the 10.5 mL of water needed for 
the reaction. A rubber top will be cut to size and glued into place. There is a square space for a 
rubber tab to act as a physical separation between the water and LiCl. The ledges above and below 
the tab space have the function of holding the rubber tab in place. The inner tube will hold the 10.5 
mL isopropyl alcohol and ChloraPrepTM solution. This tube is closed off by another physical 
separation tab made of rubber. The outside of this inner tube will hold the 7 g LiCl. The angled 
edge is where the sponge applicator will be secured. To use, pull the first tab that separates the 
water from the LiCl. When the water rushes in, the reaction will start and produce heat to warm 
the ChloraPrepTM solution. Then, the second tab can be pulled and cause the ChloraPrepTM solution 
to soak the sponge. The applied solution should feel warm on the patient’s skin.  
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Figure XVII – Final Design Model 
 
 
7.2 Warming Results Achieved  
The results from testing the temperature of the LiCl and water reaction and temperature of 
IPA showed that as the reaction increased temperature, so did the IPA.  
When the team self-tested with IPA warmed to 35°C, there was a clear drop in temperature 
of the skin immediately after application, but the initial shocking cold sensation was less. After 
180 seconds, the temperature of the skin dropped 2.8, 2.0, 1.3, and 0.43°C for Costi, Kaur, Kolaya 
and Ricciuti, respectively. These results compared to IPA at room temperature can be seen in Table 
XVI. The warmed self-testing made it clear to the team that the minimum temperature that the 
antiseptic solution should be warmed to is 35°C. Although a warmer temperature would also 
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increase patient comfort, the team believes that 35°C is the minimum required to reduce the 
chilling sensation.  
The team then self-tested with IPA warmed to 40°C. The results from this testing can also 
be seen below in Table XVII. Although numerically the results are not very different than the 35°C 
testing, the team agreed that this round of testing felt much more pleasant, and that 40°C should 
be the target temperature to warm the antiseptic to.  
 
Table XVII – Change in Skin Temperature Upon Application of Isopropyl Alcohol 
Change in Skin Temperature Upon Application 
  A B C D 
IPA at  
Room Temperature 
3.8 2.9 4.5 4.0 
IPA Warmed  
to 35°C 
2.8 2.0 1.3 0.43 
IPA Warmed  
to 40°C 
1.6 1.2 2.4 1.6 
 
 
7.3 Antimicrobial Properties Maintained  
The team completed antimicrobial testing with warmed ChloraPrep solution in order to 
ensure that its original functionality is still maintained even after being warmed to 40°C. In order 
to determine if this was the case, the team followed EN standard 1276 and performed quantitative 
suspension tests with Staphylococcus Aureus and three tests groups – a sterile plate, a growth plate, 
and an experimental plate that was exposed to the warmed ChloraPrep. In order to be considered 
successful, the team needed to see a 4-log reduction in bacteria count on the experimental plate. 
After performing three replicates and counting the bacteria on all plates, the team calculated and 
determined that all experimental plates had a 6-log bacterial reduction. This means that the team’s 
results surpassed the accepted standards. The team feels confident from these results that warming 
ChloraPrep to the target temperature of 40°C will have no effect on its antimicrobial properties.  
 
7.4 Project Limitations  
While the team would consider this a successful project, there were many obstacles faced 
along the way that are worth discussing.  
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The project was limited by time as the team only had one academic year to complete the 
project. As this year marked the proposal of the project, the team had to begin the design process 
from the begin, which made time an even greater limiting factor. It was not possible to for the team 
to create a prototype that would resemble the product the team would hope to one day see on the 
market. More time would certainly be necessary to see this device to market as the team sponsor 
had originally intended.  
One of the biggest limitations of this project was resources, particularly the resources available 
to the team in the laboratory. One challenge was a lack of autoclaved glass beakers in the lab. This 
introduced possible contamination to the antiseptic solution that the team prepped. While the 
likelihood of this solution being contaminated is very low due to its antiseptic properties, it would 
have been beneficial to work with sterile equipment regardless. Additionally, the lab lacked a lot 
of basic equipment that the team required for testing such as electronic/automated thermometers, 
calipers and glass test tubes. This was limiting as the team often had to acquire these materials, 
which would delay testing that could have otherwise been very simple. Another limitation was the 
space available to the team in the laboratory. Each MQP is allotted one bench, which was sufficient 
in terms of storage. When the team ran testing protocols, however, more space than just one bench 
was often required. This was problematic when teams on nearby benches were also in the 
laboratory because there was often not enough space for both teams to conduct testing 
simultaneously.   
In addition to resources, the team was limited in their testing due to a lack of test subjects. The 
self-testing was conducted on the team members. While this was sufficient, the team recognizes 
that skin temperature can vary to a certain degree depending on several conditions. The team would 
have liked to test a larger number of subjects to validate the data further and obtain more 
statistically significant data. Unfortunately, this would have required additional IRB approval, 
which was not feasible for the scope of this project.   
Another minor limitation was lack of direction and input from the sponsor at UMass. While 
this gave the team the freedom to be creative and independent, it was limiting when the team 
needed feedback or information. For example, the survey that the team distributed at the hospital 
took much longer than expected due to difficulty in communication with the contacts there. 
The final limitation of this project was that a lot of the subject matter and background 
knowledge required for this project was not within the areas of expertise of the team members. For 
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example, a better understanding of the principles of heat transfer would have been desirable to 
make the heat transfer components of this project more straightforward. Furthermore, the team had 
limited knowledge in cell and bacteria culture and had to outsource to an additional person to help 
with this validation testing.  
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8 Conclusion and Recommendations  
8.1 Project Conclusions 
The team was able draw several conclusions upon the completion of this project. To begin, 
through heat loss testing with non-warmed ChloraPrepTM, it was determined that the application 
process is indeed an uncomfortable sensation. With this being determined, testing with warmed 
ChloraPrepTM led the team to decide that ChloraPrepTM warmed to 40°C both felt more pleasant, 
and caused a smaller heat loss from the skin during application. Additionally, the team was able 
to successfully use a lithium chloride and water heat of mixing reaction in order to warm antiseptic 
solution to this target temperature, meaning that we hit our target objective of making 
ChloraPrepTM more comfortable. The team also concluded that warmed ChloraPrepTM remains as 
effective as an antimicrobial agent than non-warmed ChloraPrepTM, through our antimicrobial 
testing. The team concludes this project to overall be successful and hopes that in the future the 
design can be continued to be perfected, and hopefully used in hospitals in the future. 
 
8.2 Future Recommendations 
           Throughout the course of this project, the team has developed recommendations for the 
continuation of the device design in the future. These recommendations mainly stem from the 
project limitations, specifically time and resources. The team hopes that with these 
recommendations, this project can be continued and improved upon in the future.  
 
8.2.1 Recommended Applicator Materials 
Moving forward from the end of this project, the team has recommendations for the 
continuation and improvement of the skin preparation applicator design. The first recommendation 
is regarding the material of the applicator. Due to manufacturing limitations, the team did not get 
to utilize what they recommend being the final material for their applicator. The team was limited 
to 3D printing in a rapid prototyping lab, and thus all prototypes were printed with varying 
materials. However, it is important to carefully select a final material for mass manufacturing, 
because the device will contain isopropyl alcohol, which is known to degrade certain plastics. The 
team recommends future versions of this device to be manufactured using HDPE or LDPE. Based 
on compatibility charts found during our research, HDPE shows no damage after 30 days of 
exposure of IPA (“Chemical Compatibility Chart”, n.d.). This means that even if the applicators 
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were stored in a medical facility for up to a month, degradation of the applicator material will not 
be a concern. LDPE is also a recommended material for the applicator because it is commonly 
used to make IPA storage containers. If possible, creating the applicator out of this material will 
ensure no degradation from IPA occurs (US Plastics Corp., n.d.).  
When selecting a material to be used in the final applicator design, it is also important to 
ensure adherence to industry standards. Although not as strict as materials being placed in the 
body, there are still standards in place for any materials regarding medical devices and entering 
operating rooms. The first standard to adhere to is “ASTM F619-14: Standard Practice for 
Extraction of Medical Plastics”. ASTM is the American Society for Testing and Materials – a 
group that publishes voluntary technical standards (ASTM International, 2014). This standard is 
used for the evaluation of raw materials, auditing materials within the manufacturing process, and 
testing of final products. The team recommends that this standard, although voluntary, be adhered 
to during the manufacturing process in order to ensure the use of high quality, safe materials.  
An additional standard to follow regarding materials is “USP 661.2 Plastic Packaging 
Systems for Pharmaceutical Use” (USP, n.d.). USP is the United States Pharmacopeia, a yearly 
publication by the United States Pharmacopeial Convention.  This standard considers safety 
aspects of a product’s packaging system based on chemical structures (USP, n.d.). USP Performs 
extractables and leachable testing, both which will be essential for our product. Following this 
standard and testing procedure, it can be ensured that there are no leachables from isopropyl 
alcohol, which would make the device unsafe for use.  
 
8.2.2 Future Testing 
Due to time constraints, the team was unable to complete all of the testing that was 
initially planned. In the future, the team recommends that the effectiveness of the antiseptic 
solution be tested on additional strains of bacteria including Escherichia coli and Pseudomonas 
fluorescens. The team was able to successfully test with Staphylococcus Aureus, a common skin 
bacterium, but it would be beneficial to complete testing with additional bacteria strains. 
Furthermore, the team would recommend warming the antiseptic solution to various temperatures 
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to determine at what temperature the antiseptic becomes ineffective. These varying degrees of 
warmed antiseptic should then be utilized in the antimicrobial testing.  
Additionally, the physical antiseptic applicator design needs future development. As 
previously stated, the team recommends that the body of the device is manufactured via blow 
molding or injection molding with HDPE or LDPE. However, the pull tabs are currently made 
from rubber. These rubber tabs were not fully leak proof – additional testing will be required to 
determine if it was the rubber material or tab shape that caused the leaking. A cap will also need 
to be designed in order to hold the contents of the applicator fully in the device. Currently, there 
is an open end to the applicator, meaning that it has not yet be fully designed.  
Finally, the team recommends testing of the heat of mixing reaction and warming of the 
antiseptic within the device. The team was only able to measure the heat of mixing in an open 
beaker, rather than in the device, and it was difficult to account for heat loss to the open air. It will 
be critical to test the reaction within the closed device in order to ensure that heat transfer can 
occur through the final chosen device material.  
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Appendices  
 
Appendix A 
Appendix A includes the patient experience questionnaire that was given to Interventional 
Radiology department at UMMS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
-------------------------------------------------------------------------------------------------------------------------------------------------- 
MEDICAL PERSONNEL ONLY  
-------------------------------------------------------------------------------------------------------------------------------------------------- 
1. Which bodily region required skin preparation for the procedure? What procedure was 
performed? 
 
 
 
2. How important is warming the skin preparation stick to the overall patient experience? Please 
circle an option below!  
 
1 - very unimportant 
2 - somewhat unimportant  
3 - neutral 
4 - somewhat important  
5 - very important 
Comments:  
 
 
 
 1 
 
Interventional Radiology Department 
Patient Experience Questionnaire 
 
This questionnaire is designed to support a research project, sponsored by Dr. Sarwat Hussain, that is being 
executed by a team of biomedical engineering students at Worcester Polytechnic Institute. Your input is crucial 
and valuable in guiding the project’s need, scope, research and design components. If you decide not to 
answer these questions, your care will not be affected in any way. 
 
1. How do you feel about the temperature of the skin preparation solution? 
 
1 – Shockingly cold 
2 – Very cold 
3 – Cold  
4 – Neutral 
5 – Warm 
6 – Very Warm  
7 – Shockingly Warn 
8 – Unsure 
9 – Did not notice 
Comments:  
 
2. What can be done to improve your experience with the skin preparation? 
 
 
 
 
 
3. Would your experience have been better if the antiseptic solution was warm?  
 
Yes 
No 
Doesn’t Matter 
 
 
THANK YOU FOR YOUR TIME AND INPUT! 
The project team would like to ensure that your personal information and opinions will not be disclosed to 
individuals outside of this project team. 
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Appendix B 
Appendix B include the WPI IRB Approval for the patient questionnaire in Appendix A. 
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Appendix C 
Appendix C includes results from the patient questionnaire in Appendix A. 
 
 
Figure C1. Responses to Question 1: “How do you feel about the temperature of the skin preparation 
solution?” 
 
“What can be done to improve your experience with the skin preparation?” 
Patient did not 
answer question 
“to be warmed” “warm” “make it warmer” “hot” 
“warming could 
benefit some 
patients” 
“warm” “warm” “warmer” “warmer” 
“warmer” “warmer” “to be warm “warmer” 
 “hot” “warming” “warmer” “to be warm” 
Patient did not 
answer question 
“nothing” “warmer” “to be warm” 
Figure C2. Responses to Question 2: “What can be done to improve your experience with the skin 
preparation?” 
36%
41%
18%
5%
"How do you feel about the temperature of the skin preparation 
solution?"
shockingly cold
very cold
cold
neutral
warm
shockingly warm
unsure
did not notice
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Figure C3. Responses to Question 3: “Would your experience have been better if the antiseptic solution was 
warm?” 
 
 
 
 
 
 
  
91%
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"Would your experience have been better if the antiseptic 
solution was warm?"
Yes
No
Doesn't matter
  
 
92 
 
Appendix D  
Appendix D contains the EN Standard Protocol for the antimicrobial testing that was performed.  
 
Requirements:  
The product, when tested in accordance with the test protocol described above, shall demonstrate 
at least a 104 log reduction in viable counts when the test organisms are Pseudomonas 
aeruginosa, Staphylococcus aureus, Escherichia coli and Enterococcus hirae.  
  
Test Method:  
Prep  
1. Subculture culture from the stock culture by streaking onto TSA agar and incubate overnight.  
2. Make a second subculture and incubate as earlier.  
3. The second subculture is the working culture. Bacterial test suspensions are prepared by taking 
10 ml of diluent (Tryptone Sodium Chloride solution) in a 100 ml flask with 5g of glass beads.  
4. From the working culture a loopful of bacterial cells is transferred into the diluent and 
suspended. Flask is shaken 3 minutes using a mechanical shaker  
  
Test  
1. Pipette 8 ml of the test products in to container of suitable capacity and add 1ml of water.  
2. Add 1ml bacterial suspension containing 1.5x108 cfu/ml to 5 x108 cfu/ml and 1ml of 
interfering substance (0.3/3g/l BSA) after incubating these two 2 minutes.  
3. Immediately start the stopwatch, mix and place the container in the water bath at 20°C.  
4. The activity of the product shall be determined for a contact time chosen from one of the 
following: 1min, 5min, 15min, 30min, 45min, 60min.  
5. At the chosen contact time, pipette 1ml of the test mixture into a tube containing 8ml 
neutralizer (30g/l polysorbate 80 + 3g/l lecithine) and 1ml of water. Mix and incubate in the 
water bath for 5 minutes.  
6. After neutralization take a 1ml sample in duplicate and transfer on TSA plates.  
7. Incubate the plates in 36°C for 24 hours. Count the plates and determine the number 
of colony forming units for each plate.  
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Results:  
For each test organism record the number of cfu/ml in the bactericidal test suspension (N) and 
after the test procedure for bactericidal activity of the product (Na).  
  
Conclusion:  
The product shall be deemed to have passed the test if it demonstrates a 104 or more reduction in 
viability of test organism within 60 min or less at 23°C.  
  
  
 
 
 
